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ABSTRACT
BIOPHYSICAL CHARACTERIZATION OF A DE NOVO ELASTIN

by
Kelly Nicole Greenland

Adviser: Dr. Ronald L. Koder

Natural human elastin is found in tissue such as the lungs, arteries, and skin. This protein
is formed at birth with no mechanism present to repair or supplement the initial quantity formed.
As a result, the functionality and durability of elastin’s elasticity is critically important. To date,
the mechanics of this ability to stretch and recoil is not fully understood. This study utilizes de
novo protein design to create a small library of simplistic versions of elastin-like proteins,
demonstrate the elastin-like proteins, maintain elastin’s functionality, and inquire into its
structure using solution nuclear magnetic resonance (NMR).
Elastin is formed from cross-linked tropoelastin. Therefore, the first generation of
designed proteins consisted of one protein that utilized homogony of interspecies tropoelastin by
using three common domains, two hydrophobic and one cross-linking domains. Basic
modifications were made to open the hydrophobic region and also to make the protein easier to
purify and characterize.
The designed protein maintained its functionality, self-aggregating as the temperature
increased. Uniquely, the protein remained self-aggregated as the temperature returned below the
critical transition temperature. Self-aggregation was additionally induced by increasing salt
iv

concentrations and by modifying the pH. The protein appeared to have little secondary structure
when studied with solution NMR.
These results fueled a second generation of designed elastin-like proteins. This generation
contained variations designed to study the cross-linking domain, one specific hydrophobic
domain, and the effect of the length of the elastin-like protein. The cross-linking domain in one
variation has been significantly modified while the flanking hydrophobic domains have remained
unchanged. This characterization of this protein will answer questions regarding the specificity
of the homologous nature of the cross-linking domain of tropoelastin across species. A second
protein has additional hydrophobic domains flanking the originally designed elastin-like protein.
The characterization of this protein will answer questions regarding the functionality of longer or
more hydrophobic elastin-like proteins. The final variation designed is one hydrophobic domain
and the new cross-linking domain repeating several times. The characterization of this protein
will answer questions regarding the specific hydrophobic domain and its functionality.
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CHAPTER 1: INTRODUCTION

This dissertation is aimed at gleaning new information regarding elastin by studying
small model elastin-like proteins that contained strong homology with the monomeric protein
tropoelastin which forms elastin when cross-linked with additional copies of tropoelastin. This
work is broken down into several sections: background, which pertains to techniques utilized in
the study of the model proteins, literature review, which briefly covers what other studies have
been done with tropoelastin model elastin-like proteins, the new research that was done, and
future directions to lead subsequent investigations.
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CHAPTER 2: BACKGROUND

2.1: PROTEIN BACKGROUND

2.1.1: AMINO ACIDS
Proteins are comprised of twenty amino acids grouped into general categories of polar or
non-polar, charged or uncharged, hydrophobic or hydrophilic, or if they possess special
properties as seen in Figure 1. Polar amino acids can further be separated into positively charged,
negatively charged or non-charged species, as depicted below. The special properties that can
typically be utilized to characterize amino acids include aromatic side chains, side chains that
can form disulfide bridges, or side chains that have unique folding properties.3
Amino acids are traditionally read from the amine NH3+ terminus to the carboxylic acid
COO- terminus. They are attached to each other via a peptide bond when the hydroxide on the
carboxylic acid terminus is removed upon reaction with the amine terminus of another amino
acid, forming water and bonding the two termini together. The two amino acids are then linked,
forming the beginning of a protein backbone.4

2

FIGURE 1: AMINO ACIDS 1
The twenty amino acids separated into common traits. A. Amino acids
with charged side chains. B. Amino acids with polar but uncharged side
chains. C. Special case amino acids. D. Amino acids with hydrophobic
side chains.
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2.1.2: PRIMARY STRUCTURE
As mentioned earlier, a protein is a bonded chain of amino acids. Thus the primary
structure is the sequential order of amino acids. As an example, a protein that will be discussed
later, 20’_21-23_24’21-23_24’, contains 182 amino acids, with the primary structure of the
protein displayed in Figure 2. Each amino acid has been represented by either a one-letter
symbol designation instead of the full name for each amino acid or the three letter designation
seen in Figure 1. The one-letter designation for each amino acid is listed in Figure 3.

WVPGVGGVPGVGGVPGVGGVPGVGGVPGVGGV
EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVW
FIGURE 2: PRIMARY SEQUENCE OF 20'_21-23_24'_21-23_24'
Protein 20’_21-23_24’_21-23_24’ is hydrophobic domain 20’, the first line of the sequence,
followed by cross-linking domain 21_23, which is the second and fourth line of the sequence.
This connects to the hydrophobic domain 24’ which is the third and fifth line of the sequence.
Hence, the name of the protein is each domain as it appears in the sequence.

4

FIGURE 3: ONE LETTER AMINO ACID CODE
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2.1.3: SECONDARY STRUCTURE
Protein secondary structure is the initial folding of areas of the protein into lower energy
conformations. The most common structures, alpha helices and beta sheets, are displayed in
Figure 4. A complete understanding of folding is still an unsolved problem in biophysics, but
progress has been made5. Proteins are believed to fold due to driving forces including
hydrophobic interactions, hydrogen bonds, ion pairs, and space-limiting Van Der Waals
interactions.6

FIGURE 4: PROTEIN SECONDARY STRUCTURE 7
On the left is an example of an alpha helix and on the right is an example of a beta sheet, two of
the most common examples of secondary structure within a protein.
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2.1.4: TERTIARY AND HIGHER ORDER STRUCTURE
Tertiary structure of a protein is formed when the entire protein completely folds into the
lowest conformational energy state. This structure may have one or more secondary structures
with or without unfolded areas. Quaternary structures are possible when multiple proteins, or
copies of the same protein, come together into a unique structure that further reduces the energy
state of each protein. A common example of this is hemoglobin, which has two copies of chain A
and two copies of chain B associated into a heteroquartamer, as is seen in Figure 5.
One could argue that elastin’s quaternary structure is cross-linked monomeric
tropoelastin. However, this also raises technical issues since lysyl oxidase is required to modify
the cross-linking lysine residues before the tropoelastin can cross-link to form elastin.

Figure 5: Hemoglobin2
Hetero-tetramer hemoglobin imaged with two A subunits in
red and two B subunits in blue.
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2.2: CHARACTERIZATION BACKGROUND
Proteins possess a plethora of properties that allow them to be studied. Several noninvasive methods of characterization which do not require high concentrations of proteins utilize
ultraviolet and visible wavelengths of light to identify properties of the protein. These techniques
were utilized to characterize proteins within this study and merit a brief explanation.

2.2.1: ULTRAVIOLET-VISIBLE SPECTROSCOPY
Ultra-violet (UV-Vis) spectroscopy uses light in the 200-1000 nm wavelength region to
excite ground state electrons to available excited states.8 The transition is called absorption, as
the photon is “absorbed” by the electron in the ground state and used to transition to the excited
state. The energy released when the electron transitions back to the ground state is typically
thermal energy; there is no photon emitted. The spectrophotometer, the machine used in UV-Vis
spectroscopy, measures the intensity of the photons passed through a solution sample and
compares it to the initial intensity of the photons. The spectrophotometer then takes the negative
logarithm of final intensity divided by the initial intensity; the resulting value is absorbance.

𝐴 =‒ log

𝐼𝑓

()
𝐼𝑖

(1)

Beer’s Law states that the absorbance, A, is linearly related to the concentration of the
absorbing species, listed as C in Equation 2.
(2)

𝐴 = 𝜖𝐶𝐿

This allows for the determination of the concentration of a sample of protein that contains
tryptophan, since tryptophan absorbs photons strongly at 280 nm. Additionally, the length of
8

sample that the photon passed through is needed, L, is typically 0.4 or 1.0 cm, and depends on
the sample container. The final variable is known as the extinction coefficient, which is a
measurement of the strength that a species absorbs photons. This value is known for each amino
acid and the total can be calculated from a protein’s primary structure. This is often
accomplished by inputting the sequence into online calculators such as ExPASy ProtParam tool.9
The caveat of UV-VIS spectroscopy is that the absorbance value needs to be kept at or
below 1.0 because above 1.0 the linear relationship begins to break down. As a result, the highly
concentrated samples needed for solution NMR cannot be measured completely. As such, the
concentration can be determined by one of two methods, though both methods can introduce
error; the degree of error dependent on the accuracy of the volume measurement.
The first method is to measure the concentration of a dilute sample and then concentrate
it. Then, using the ratio of initial dilute volume to final concentrated volume, it is possible to
determine the final concentration. This method can have significant errors if, for example, the
initial volume is 15.0 mL as measured by a 25 mL pipette, which has an accuracy of 1 mL, then
the sample is concentrated down to 1 mL, as measured by a 1 mL pipette, which has the smallest
division of 2 uL. The uncertainty of the initial volume is half the final volume. A thorough
uncertainty derivation is difficult to determine because the absorbance varies, as it is dependent
upon the equipment’s lamp, the temperature, and the scale utilized.
A second method for determining the concentration of a highly concentrated sample is to
take 10 uL of sample and add it to 990 uL of buffer. This process typically dilutes the sample to
a level that will be within the linear region of the spectrophotometer. Next, the dilute sample’s
determined concentration value is multiplied by 100 in order to determine the concentration of
9

the high concentration sample. The ratio does not need to fall in a range of 10 uL to 1 mL if the
sample will yield an absorbance value less than 0.1, as the error rate of the absorbance is higher
at lower levels. This method also yields potential error if a low absorbance value is recorded for
the diluted sample. Additionally, inaccurate measurements may be an issue, but typically the
volumes used for this method are measured with glass syringes that have 0.25 uL smallest
divisions and 10 uL divisions for the 25 uL volume syringe and 1 mL volume syringe,
respectively.

10

2.2.2: SCATTERING
An additional application of UV-VIS spectroscopy is the ability to detect light scattering.
As scattering characteristics are dependent upon the size of the particle in solution, it is necessary
to have an idea of the size of the particle. The scattering assay used in this project began with
molten-globular protein and as the conditions were modified, it self-aggregated into larger and
larger particles. Fundamentally, a 500 amino acid folded protein has an average diameter of 2-3
nm. The largest protein studied with this experiment had 254 amino acids, and even if the
protein is molten globular instead of in a unique fold, all proteins can be approximated as 2-3 nm
in diameter at the largest. This is 100 times less than the lowest wavelength used in scattering.
Consequently, in the regime wherein the proteins have not begun to self-aggregate, Rayleigh
scattering approximations are valid. However, because the Rayleigh approximation states
particles are at least ten times smaller than the wavelength of the light, as the proteins begin to
self-aggregate, the particles become much larger and are no longer valid.
One assay completed had 10 uL of solution removed every 5˚C and the samples were
placed on glass slides, covered, and sealed. When imaged by a confocal microscope, it was
possible to see particles as small as 2 um. Samples taken at temperatures above the critical
coacervation temperature had structures that exceeded 50 um. All visible particles were orders of
magnitude larger than the wavelength of the light used in the UV-VIS spectrophotometer, so
while Rayleigh was no longer the correct scattering regime, it was clear that the light was still
scattered.
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As previously stated, when the proteins have not begun to self-aggregate, any scattering
present falls under Rayleigh scattering. In Rayleigh scattering, the intensity of light scattered is
proportional to the inverse wavelength to the fourth power, as seen in Equation 3.
𝐼 ∝ 𝐼𝑜

()
1

𝜆4

(3)

This relationship demonstrates a dependence upon the wavelength of the light that
samples the solution. The shorter wavelengths on the blue end of the spectra are therefore
scattered more than the longer wavelengths on the red of the spectra. This phenomenon can be
seen in scattering assay data presented in Figure 6, particularly in the 50˚C data curve.
Once the proteins began to self-aggregate and were on the same scale as the wavelength
of light, the scattering entered the Tyndall regime. This scattering is what gives the appearance
of milk to be slightly blue, as well as motorcycle exhaust. While Tyndall scattering does not
have a rigorous mathematical formulism, if the particle is assumed to be spherical, it can be
represented by Mie scattering, an analytical solution to Maxwell’s equation using an infinite
series expansion.
It is evident from the assay that as the particles become larger the wavelength dependence
changes. As the particles become very large the wavelength dependence appears to be
minimally impacted. This phenomenon can be seen in Figure 6, with both the 90˚C and 100 ˚C
data. Occasionally, the particles became so large that the scattered light was not detected and the
scan had to be repeated when the large particle was no longer in the path. That was believed to
be the initial case for the 100˚C data, but after several repetitions it was concluded that the data
accurately represented the scattering of the large size particles.
12

SCATTERING ASSAY
0.55

5c

0.5

50c

90c

100c

0.45

ABSORBANCE

0.4
0.35
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FIGURE 6: SCATTERING ASSAY
Scattering assay of 25 uM 20’_21-23_24’_21-23_24’ in 50 mM Tris, 1 mM CaCl2, pH 6.0.
Temperature was increased from 5˚C to 100˚C at 1˚C per minute with constant stirring. The 5c
shows slight scattering, while 50c shows more significant Rayleigh scattering. The 90c and
100c data shows scattering from particles at least on the same size scale as the wavelength of
the light.
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2.2.3: CIRCULAR DICHROISM
While circular dichroism (CD) was not completed on the proteins in this work at
the time of publication, it is a characterization tool which will be utilized. CD is a nondestructive method of protein characterization that needs only a low concentration of protein.
CD utilizes a small volume of protein in solution in a narrow cuvette that is inserted into a CD
Spectroscopy apparatus. This machine utilizes the same mechanism as absorption spectroscopy
utilized in UV-VIS spectroscopy. CD spectroscopy differs from UV-VIS spectroscopy in that the
light used to excite the electrons of the protein is polarized.
Light is an electromagnetic wave; the electric field is perpendicular to the magnetic field.
Non-polarized light has the components, while still perpendicular, at all different angles so that
they average to zero. Linearly polarized light can be thought of as light that has gone through a
picket fence. The “fence” would block any wave whose electrical component is not vertical,
resulting in all light that has a completely vertical component. In our scenario the picket fence
represents a polarizer. In reality, a linear polarizer tends to have a composition wherein long
strands are connected excite along the strands but not between the strands. In this case, the
waves are transmitted through the long strands but any waves that are not along the direction of
the strands will be disrupted.
Circularly polarized light is similar to linearly polarized light except the axis of
polarization rotates either clockwise or counterclockwise. The creation of circularly polarized
light is most easily created in a two-step process wherein which non-polarized light first passes
through a linear polarizer then through a second quarter-wave polarizer. The quarter-wave
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polarizer is made of a media that allows light to pass through in one direction quickly while
passing more slowly perpendicularly. This results in a net circular polarization.
The circularly polarized light is utilized in assays because left-handed circularly polarized
light passes through absorbing material at a different rate than right-handed circularly polarized
light. This difference can be detected with the equipment. The difference relates to the chirality
of the protein, which relates to the fold of the protein and not the actual structure; E. coli
expresses the proteins with amino acids of the same natural chirality.

FIGURE 7: EXAMPLE SIGNALS OF VARIOUS PROTEIN CD CONFORMATIONS 10
The Solid line is alpha helical protein, long dashed line is anti-parallel beta sheet and short
dashed line is irregular structure.

15

Figure 7 shows the two most common protein secondary structures and their CD signals. With
the possible exception of the termini, which may be small, non-folded regions, the alpha helical
signal was created by using a protein that is completely helical. The beta sheet signal was
likewise created by using a protein that is completely folded into the beta sheet conformation
with only minimal areas not folded, such as the turns needed to stack the sheets and the termini
which may be unfolded. The irregular structure is from a protein which has either no or minimal
secondary structure. From these three signals and libraries of similar signals, it is possible to
determine information from a protein whose secondary structure is unknown. Algorithms have
been created that utilize these large libraries of signals to de-convolute the unknown signal and
give the relative percentage of different structures.11
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2.3: NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY BACKGROUND
Nuclear magnetic resonance (NMR) spectroscopy can be utilized to characterize proteins
in a non-destructive fashion, similar to UV-Vis spectroscopy. Crystallography can also
determine three-dimensional structure. However, only NMR can be utilized to investigate
kinetics and dynamics of proteins.12
Protein NMR utilizes a characteristic of certain nuclei whose spin angular momentum is
½. Spin angular momentum is a quantum mechanics phenomenon intrinsic to all nuclei. Nuclei
that have an odd number of total neutrons have a spin angular momentum of at least ½; the most
commonly studied nuclei being 1H, 13C and 15N. Additionally, 2H is used, which has a spin
angular momentum of 1. Proteins with all or some of these nuclei are placed in a strong
magnetic field that orients the nuclei along the field. Then electromagnetic radiation at resonant
radio frequencies is pulsed to perturb the aligned nuclei. The nuclei absorb and re-emit the
radiation that can be detected, amplified, and mathematically converted into useful information
about the nuclei. This phenomenon is called chemical shift. The chemical shift is dependent
primarily upon the local environment and can be utilized to determine structure and kinetics of
the nuclei. Chemical shift peaks are reported in terms of parts per million (ppm), which is the
difference in magnetic field strength.
However, NMR has some drawbacks which include: NMR sample concentrations are
significantly larger than UV-Vis samples, NMR often requires a large time commitment on the
equipment, and the equipment is expensive.
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2.3.1: ONE DIMENSIONAL SOLUTION NMR
One dimensional NMR is the first experiment run on a new protein. The spectrum is
used as a baseline to compare subsequent samples and conditions. Very small proteins, with less
than 20 amino acids, have the potential to be nearly fully defined with 1D experiments.
However, as seen in Figure 8, ubiquitin, a protein with 62 amino acids, the chemical shifts
overlap to the point where it is impossible to differentiate 62 peaks.
In 1D NMR the 1H nuclei are excited with electromagnetic energy corresponding to the
resonance frequency. Then the signal from the 1H nuclei is detected, amplified and converted
from the time domain using a fourier transform. This experiment required the shortest length of
time on the spectrometer, and the number of repetitions depended on sample concentration.

FIGURE 8: UBIQUITIN 1D NMR 13
One-dimensional solution NMR spectrum of the 62 amino acid protein ubiquitin.
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2.3.2: TWO DIMENSIONAL SOLUTION NMR
Two dimensional NMR was used extensively in this research as a method to probe ideal
conditions for further studies. The most frequently utilized experiment was 15N Hetero Single
Quantum Coherence spectroscopy (15N-HSQC). This experiment excites the 1H and then
transfers the energy to the 15N, which in turn transfers energy back to the 1H, which is then
detected and transformed to chemical shift. Multiple scans are completed, modifying the 15N,
indirect, dimension while the entire 1H, direct, dimension is run with each scan. The time
devoted in this experiment is therefore dependent upon the concentration of the protein and the
number of scans in the indirect dimension.
A NHSQC is capable of relaying folding information regarding a protein as well as
aggregation. An unfolded protein will have most peaks all together around 8.0 ppm, while a
folded protein will have peaks well dispersed from below 7.0 ppm to 9.0 ppm and even higher.
Figure 9 demonstrates a protein completely unfolded, partially folded and fully folded, and the
corresponding NHSQC spectra for each condition.

FIGURE 9: APOLMYOGLOBIN NHSQC NMR 14
Apolmyoglobin at various pH resulting in unfolded, partially folded and fully folded protein.
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2.3.3: THREE DIMENSIONAL SOLUTION NMR
Three dimensional NMR was used in this study to investigate the structure of
proteins. The first experiment generally run is an HNCO. This experiment utilizes 1H, 15N and
13C

isotopes. The experiment scans over the full range of 1H at selected values of 15N and 13C to

create slices similar to those in 2D NMR.
Figure 10 is an example of the data set that is collected in an HNCO experiment. On the
left is a 3D representation while on the right are two slices; the bottom is at a constant 15N and
the top is at a constant 13C value.

FIGURE 10: 3D REPRESENTATION OF HNCO SPECTRA 15
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The rationale in first running an HNCO as the first 3D NMR experiment can be seen in
Figure 10, on the top right. When all the 13C planes are compressed down onto one 1H-15N
spectra, it should be identical to the NHSQC that is collected via 2D NMR. Therefore, by
running this experiment first, it is possible to check parameters and conditions again to maximize
resolution, sensitivity, and signal separation before proceeding to the additional suite of 3D
NMR experiments.
Typically, 3D NMR experiments geared towards structure determinations are run in
pairs. Once a good HNCO spectra has been collected, its pair, the HN(CA)CO, is often run. The
reason pairs of experiments tend to be run is the way in which the magnetic energy is transferred
from one isotope to another. As seen in the top left of Figure 11, the HNCO experiment starts
by the excitation of 1H, which then transfers to 15N. Then the energy is transferred only to the 13C
labeled CO to the left, which is the preceding amino acid along the backbone, often referred to as
the i-1 residue. The HN(CA)CO transfers the energy from the 15N to both the i-1 residue and the
ith residue. This is accomplished by transferring through the CA atom, but as it is not the desired
signal, the experiment is not tuned to detect the energy from this atom.
As seen in Figure 11, the HN(CO)CA and HNCA are also run as a pair where the CA
atom is the desired signal from both the i-1 residue and the ith residue. This is also the case for
the HN(CO)CACB and HNCACB experiments. For these experiments, both the CA and the CB
signals are desired whereas the CO is not. The rationale for not simply exciting the CA and CB
is due to sensitivity issues resulting from magnetic flux, relative population of isotope, and other
factors. The sensitivity of 13C is 64000 times less sensitive than 1H. It is for this reason that 1H is
first excited and then the energy transferred to the other isotopes. Subsequently, the energy is
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usually transferred back to be detected. However, this method can take a long time, which allows
for relaxation and the decay of signal. Because of this, many researchers choose to run a
CBCA(CO)NH instead of an HN(CO)CACB, wherein the CB is directly excited and the energy
is transferred to the 1H for detection.

FIGURE 11: 3D NMR EXPERIMENTS 16
Pairs of 3D NMR experiments run for backbone assignment of proteins. The top line of
experiments is used to identify the i-1 and ith CO. The second line of experiments is used to
identify the i-1 and ith CA. The bottom line of experiments is used to identify the i-1 and ith CA
and CB atoms.
With these spectra collected, they can be analyzed to connect ith atoms from plane to the
i-1 atom. This pattern can be extended to form a chain of atoms that match and begin to form a
chain of the atoms in the backbone. Ideally, this chain can be extended forward and backward to
completely identify each atom in the backbone. An example of this process can be seen in Figure
12. The far left column is an i-1 atom highlighted in red for the CB on the top row, CA on the
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middle row and CO on the bottom row. This is then matched with the ith atom of another scan.
This process can then be continued to connect the backbone. One difficulty in this process is that
the amino acid proline does not have an ith atom peak due to its unique side chain structure. As a
result, this breaks the backbone chain into pieces at each proline appearance.

FIGURE 12: 3D NMR PROCESSING 17
Chaining corresponding chemical shift peaks to assign the backbone of a protein. The far left
column represents one set of peaks corresponding to the i-1 and i-2 amino acids of the backbone,
the second column represents the i-1 amino acid, and the third column has the i-1 and the ith amino
acid. The far right column has the ith amino acid as well. The top row is the CB chemical shifts, the
center row is the CA shifts and the bottom row is the CO chemical shifts.
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CHAPTER 3: LITERATURE REVIEW
3.1: MINIATURE TROPOELASTIN
Tropoelastin contains two primary domains: a hydrophobic non-polar region and a
hydrophilic cross-linking region. The hydrophobic non-polar region primarily contains the amino
acids valine, proline, alanine and glycine. These amino acids typically appear in motifs that
repeat four, five or six times. Common motifs include: Val-Pro-Gly-Gly, Val-Pro-Gly-Val-Gly,
and Ala-Pro-Gly-Val-Gly-Val. In contrast, the hydrophilic region contains many alanine and
lysine residues which are responsible for the cross-linking of tropoelastin to form elastin. It is
believed that while the hydrophilic regions are responsible for cross-linking, the hydrophobic
domains are responsible for the mechanical properties of elasticity within tropoelastin and
elastin.18
Tropoelastin is found in many other species where one would expect elastin’s functions
to facilitate respiration and blood flow, such as in chickens, rats and cattle. The sequences of
tropoelastin and the genes that encode this protein within humans and the above mentioned
animals are very similar and possess a high-level of homology.19
Small proteins designed from repeats of the motifs listed above have been designated
ELPs, elastin-like proteins. These small proteins can be used to functionalize desired proteins for
purification by fusion to the end of desired protein. This process has been designated
ELPylation.20
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3.2: COACERVATION
Coacervation is the reversible self-aggregation initiated by temperature changes. This
inverse phase transition of tropoelastin is termed the transition temperature, and it occurs in a
narrow window of temperature variation, typically 2-3°C. The self-aggregation can be monitored
by measuring scattering and turbidity of the protein solution using UV-VIS spectrophotometry.
Below the transition temperature the proteins are soluble and do not scatter photons. Above the
transition temperature, the protein self-aggregates and becomes insoluble, scattering photons and
increasing turbidity.21,22 Self-aggregation and turbidity is completely reversed when the
temperature returns to below the transition temperature.
The transition temperature is determined by several factors including buffer, protein
concentration, salt concentration, the size of the protein, the ionization influence of side chains of
each amino acid, and the arrangement of polar interactions.23,24,25,26 The transition temperature
will decrease as salt concentration increases or as the number of repeats of the motif increases.
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3.3: CROSSLINKING
3.3.1: LYSYL OXIDASE
According to Eyre et al lysyl oxidase is the only chemical needed to cross-link collagen
and elastin. It is believed that amino acids near the lysine that are cross-linked have developed as
active sites to promote cross-linking. Lysyl oxidase functions by converting the amine side
chains of lysine and hydroxylisine into aldehydes.27 Then the aldehydes condense to covalently
cross-link.28 The crystal structure of lysyl oxidase was determined in 2006 by Duff et al and is
shown below in Figure 13.

FIGURE 13: LYSYL OXIDASE 29
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3.3.2: OTHER METHODS
In 2007, Lim et al demonstrated use of an organophosphorous cross-linker,
β-[tris(hydroxymethyl)phosphino]propionic acid (THPP). Unlike lysyl oxidase, THPP does not
turn the amine group of the lysine into an aldehyde and condense to covalently cross-link.
Instead, the amine group of the lysine binds to a hydroxide on the THPP, releasing water.
Because THPP has three hydroxide binding opportunities, a THPP has the ability to cross-link
three different lysine amino acids. This can be seen in Figure 14.

FIGURE 14: THPP CROSS-LINK 30
Gluteraldehyde is an additional cross-linking chemical. Its cross-linking mechanism is
the same as lysyl oxidase, converting the amine of lysine to aldehyde. However, the selectivity of
gluteraldehyde is low, so it will convert all available amines to aldehyde. It is therefore used in
sterilization and is considered toxic because of its ability to convert the amine terminus of any
protein to aldehyde.
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3.4: APPLICATIONS
Given the properties of elastin-like proteins, it has been hypothesized that it should be
possible to build switchable nanostructures designed to open or close by fluctuating the
temperature.20 Additionally, the self-aggregation could make capsules to introduce nano-devices
in a biocompatible environment.31
In vitro and in vivo studies of the repeating hydrophobic motif, Val-Pro-Ala-Val-Gly,
have failed to demonstrate any cytotoxicity, general inflammation response or cellular
respiratory depression, a result indicative of strong biocompatibility.32 Their biocompatibility
and chemical similarity to human elastin makes them immunologically invisible and ideal for
biomedical applications such as drug delivery and cellular matrices.33,34

3.4.1: DRUG DELIVERY
Elastin-like proteins self-aggregate as the temperature is raised above the transition
temperature. This feature can help focus pharmaceuticals that have the elastin-like protein tag to
areas of hyperthermia.35 By focusing the pharmaceuticals to desired locations, side effects
including cytotoxic material entering undesired locations, as is typical in chemotherapy, can be
significantly reduced. There are many potential applications including encapsulation to allow for
sustained release over extended lengths of time.36 Additionally, aggregated elastin-like proteins
have a longer half-life and could be a potential depository for long-term drug delivery.37
Cell proliferation has also been seen to be inhibited when elastin-like protein tagged
protein aggregates within or nearby. This has the potential to be a thermal-dependent target for
solid tumors.38 Additionally, when the Tat peptide is tagged with the elastin-like protein, it has
been shown to inhibit cell adhesion, invasion, spreading, and migration of ovarian cancer cells.39
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3.4.2 CELLULAR MATRICES
Elastin-like proteins have been genetically designed to mimic the ocular surface
extracellular matrix. This has been useful for in vitro culture of ocular surface cells.40
Additionally, elastin-like proteins have been engineered as a hydrogel matrix to grow human
adult stem cells.41 Polymers containing elastin-like proteins have also been developed as a type
of adhesive to hold mammalian cells to culture dishes. One layer of elastin-like protein is
hydrophobically bound to the culture dish and a second layer is bound to the mammalian cells
and as the temperature is raised, the elastin-like proteins self-aggregate between the two layers
holding the cells to the dish. When the temperature is lowered, the cells are released.42

3.4.3 PROTEIN PURIFICATION
Currently recombinant proteins are typically purified using affinity chromatography,
wherein a tag is added to the desired protein that will utilize its affinity to separate the tagged
desired protein from various other proteins that may have been concurrently expressed. The
elastin-like protein domain provides a novel tag that utilizes temperature fluctuations rather than
utilizing affinity. This technique, inverse transition cycling,43 was first utilized in 1996 to purify
elastin-like proteins expressed from e-coli cells.44 Following this, in 1999, Meyer purified
desired proteins that had been tagged with elastin-like proteins. This was accomplished by lycing
cells at low salt and temperature, employing centrifugation to separate out cell debris, then
raising the temperature of the supernatant above the transition temperature, causing the elastinlike proteins to self-aggregate and precipitate. The solution was centrifuged and the precipitate
was then resuspended in low-salt buffer at a temperature below the transition temperature. This
led to a nearly complete removal of host proteins and recovery of tagged desired proteins.45
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Cleavage of the elastin-like protein tag is the final step in the inverse transition cycling
purification method listed above. This can be accomplished by treatment with specific proteases
like thrombin or factor X.20 Alternatively, an intein can be added to form a triple fusion protein,
which would induce self-cleavage upon a specific temperature or pH fluctuation. This addition
would ease scalability, as only a second round of temperature variation would need to be added,
or a variation in acidity. Then an additional centrifugation step would separate the intein bound
to the elastin-like protein tag.46
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CHAPTER 4: SYNTHETIC ELASTIN LIKE PROTEIN

4.1 BACKGROUND
Elastin is found in arteries, lungs, ligaments, arteries and skin. It is a protein comprised of
multiple tropoelastin molecules that cross-link together. Each tropoelastin contains thirty-six
small domains that are either primarily lysine rich or hydrophobic. The lysine rich domains are
responsible for the cross-linking required to form elastin. The hydrophobic regions are believed
to be responsible for the phenomenon coacervation, wherein the tropoelastin aggregates. The
process of coacervation is dependent upon several factors including pH, ionic strength of the
solution, and temperature.

FIGURE 15: TROPOELASTIN 47
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Tropoelastin is approximately 72 kDa with 724 amino acids, which is too large for traditional
NMR experiments. Additionally, at such a large size, it would be difficult to see small changes
resulting from mutations or small changes in environment. This can be combatted by
representing tropoelastin with a “minielastin” protein, which is composed of hydrophobic
regions and cross-linking regions modeled after tropoelastin’s domains.
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4.2: MATERIALS AND METHODS

4.2.1: PROTEIN DESIGN AND SYNTHESIS
The minielastin proteins that we have created were modeled off the tropoelastin domains
20, 21-23, and 24. Modifications can be seen in the protein alignment in Figure 16. These model
proteins were not designed from first concepts. Instead, the proteins were composed of selected
hydrophobic and cross-linking domains and subsequently received small modifications. The
most obvious modification was the addition of two tryptophan amino acids, one at either end of
each model protein. This was done to assist in quantifying the concentration of protein samples
using tryptophan’s strong 280 nm absorption. Additionally, many leucine and isoleucine amino
acids were replaced in the hydrophobic regions with alanine or glycine. The rationale behind this
decision was to reduce the bulk of side chains that could prevent a denser hydrophobic packing
scheme. For some of the model proteins the standard cross-linking domain, 21-23, was modified
significantly. This modified cross-linking domain is represented by 21-23’ in the naming
scheme. The original cross-linking domain was made much shorter; the glutamine was replaced
with asparagine and the tyrosine was replaced with a phenylalanine. The replacement of the
glutamine with asparagine modification changed a polar uncharged amino acid to a polar
charged amino acid, and also replaced a longer side chain with a shorter one. The replacement of
tyrosine by phenylalanine swapped one aromatic amino acid with another, but the phenylalanine
is more hydrophobic than the tyrosine, a fact that may lend itself well as a transition from the
cross-linking domain to the hydrophobic domain following it.
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20: FPGFGVGVGG I PGVAGVPGVGGVPGVGGVPGVGI P
20’: - - - WVPGVGGVPGVGGVPGVGGVPGVGGVPGVG-G
21-23: EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
21-23’: - -DAAAAAKAAKF- - - -- - - - - - - - - - - - - - - 24:
24’:

LVPGVGVAPGVGVAPGVGVAPGVGLAPGVGVAPGVGVAPGVGVAPAIGP
A-PGVG - - - - - - VAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVW

FIGURE 16: SEQUENCE ALIGNMENT
The first line of each section represents the original amino acid sequence found in
tropoelastin. The second line represents the modified amino acid sequence. The red amino
acids represent changes. The dashes represent omitted amino acids.
Four protein sequences were designed; the first sequence studied was 20’_21-23_24’_2123_24’. The non-modified counterpart 20_21-23_24_21-23_24 is a sequence that has been
extensively studied and allowed for systematic comparisons of the resulting changes made.48,49,50
The second sequence designed was 20’_21-23’_24’_21-23’_24’. This sequence took the
original modifications one step further in modifying the cross-linking domain. The modified
cross-linking domain, as seen in Figure 16, varies significantly from the original cross-linking
domain. The significant variations between 21-23 and 21-23’ were the attempt to simplify the
cross-linking domain to allow for a more thorough study of the hydrophobic domains via
solution NMR.
The third sequence designed was 20’_20’_21-23_24’_21-23_24’_24’. This sequence
was designed to test the hypothesis that a longer sequence would have a greater association
energy. Adding two additional hydrophobic domains to the protein, one at the beginning and
one at the end, created this sequence. For consistency, the initial domain added was identical to
the subsequent domain and the final domain added was identical to the previous domain.
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The fourth sequence designed was 24’_21-23’_24’_21-23’_24’_21-23’_24’. This
sequence was created primarily to study the 24’ domain. By removing the 20’ domain, the only
hydrophobic effects were necessarily the result of the 24’ domain. Additionally, the simplified
cross-linking domain was utilized to minimize the effects of the larger cross-linking domain. A
review of the sequences can be seen in Figure 17.
The genes were synthesized by GENEWIZ (South Plainfield, New Jersey). Genes
contained an N-terminus TEV cut site and were inserted into an ampicillin-resistant pET32a (+)
vector by Novagen. This construct was then cloned into E. coli (Escherichia coli) strains
NICO21 for production or DH5A for storage.
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20’_21-23_24’_21-23_24’:
15.364 kDa
182 AA
WVPGVGGVPGVGGVPGVGGVPGVGGVPGVGG
EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVW
20’_21-23’_24’_21-23’_24’:
11.483 kDa
138 AA
WVPGVGGVPGVGGVPGVGGVPGVGGVPGVGG
DAAAAAKAAKF
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
DAAAAAKAAKF
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVW
20’_20’_21-23_24’_21-23_24’_24’:
21.060 kDa
254 AA
WVPGVGGVPGVGGVPGVGGVPGVGGVPGVGG
VPGVGGVPGVGGVPGVGGVPGVGGVPGVGG
EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
EAQAAAAAKAAKYGVGTPAAAAAKAAAKAAQFG
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVW
24’_21-23’_24’_21-23’_24’_21-23’_24’: 16.895 kDa
203 AA
WAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
DAAAAAKAAKF
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
DAAAAAKAAKF
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGV
DAAAAAKAAKF
APGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVAPGVGVW
FIGURE 17: ELASTIN LIKE PROTEIN SEQUENCES
Displayed are the protein sequences of the four elastin-like proteins that were designed.
The red font indicates the 20’ domain, the blue font indicates the 24’ domain and the
black font was used for both cross-linking domains. Additional information provided
includes molecular weight and total number of amino acids in the sequence.
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4.2.2: PROTEIN PURIFICATION
The genes were transformed into DH5A and NICO21 competent E.coli cells using the
method outlined in Appendix 3: Lab Protocols. Briefly, 2 uL of the DNA received was added to
500 uL of E. coli competent cells that had been stored at -80˚C. The cells were incubated on ice
for 30 minutes. The cells were then placed in a 42˚C water bath for 45 seconds for heat shock.
The cells were then incubated for 5 minutes on ice. Then 1 mL of luria broth, LB, was added
and the cells were incubated at 37˚C for 30 minutes. Finally, 100 uL was spread onto an
ampicillin plate and incubated overnight at 37˚C.
Proteins were expressed as fusions with a thioredoxindomain and a hexa-histadine tag.
Initially, E. coli were grown for six hours until turbid in 5 mL of sterile LB. This growth was
transferred to 100 mL of either sterile LB or sterile M9 (minimal media), if the protein was to be
labeled for NMR studies. Then 100 uL of stock 100 mg/ml ampicillin was added to ensure
growth of only the ampicillin-resistant e-coli. We then added 200 uL of 500 X sterile trace metal
solution, 2.5 mL of sterile 40% glucose and 100 uL of 1000 x sterile vitamin solution to the M9.
The 100 mL growths were shaken at approximately 250rpm overnight at 37˚C. Half, 50 mL, of
the overnight growth was added to either 1 L of sterile TPP (tryptone phosphate LB) or sterile
M9 (minimal media) in the case of NMR samples. Next, 1 mL of 100 mg/ml ampicillin stock
was added to the growth, 25 mL of sterile 40% glucose, 2 mL of sterile trace metal solution and
1 mL of sterile vitamin solution. The growths then shook at 37˚C until OD600 was between 0.6
and 1.0. Protein production was then induced with 0.5 mM ITPG (isopropyl-βthiogalactopyranoside). E. coli growths in TPP were then shaken for five hours at room
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temperature, while M9 growths were shaken at room temperature at approximately 250
revolutions per minute for seven hours.
Cells were collected by centrifuging the 1 L in three containers at 4˚C at 10,000 rpm for
10 minutes. Cells were resuspended in a low imidazole-working buffer, known as wash buffer,
with 1 ug/mL DNaseI and a pipette tip of Pefabloc. Cells were resuspended by gentle rotation for
30 minutes at 4˚C. Cells were broken open using a Mini Cell Pressure Cell French press by Glen
Mills, Inc., which applied over 1000psi three times to the cells. Material collected was separated
by centrifugation at 15,000 rpm at 4˚C for 30 minutes.
Following manufacturer’s directions, the supernatant was then purified on a Ninitrilotriacetic acid column (Qiagen, Inc.). This utilized imidazole-binding affinity.
Consequently, an elution buffer was poured over the column with a higher imidazole
concentration, which replaced the locations the hexa-histadine tags had bound.
The fusion protein collected was then dialyzed overnight into 50 mM Tris-HCl, 1 mM
DTT (dithiothreitol) at pH 8.0. His6-tagged TEV protease (Invitrogen, Inc.) cleaved the fusion
protein for at least six hours at room temperature with gentle nutation. The mixture was then
dialyzed back into low imidazole-working buffer and filtered by running it back over a Ninitrilotriacetic acid column. The protein was then dialyzed into lyophilization buffer and
lyophilized. Protein was resuspended in minimal amounts of 50 mM phosphate buffer, pH 7.4,
and run on a reverse-phase HPLC (high pressure liquid chromatography) C18 prep column
(Higgins Analytical) with a water/acetonitrile gradient 30%-70% in 40 minutes with 0.2% TFA
(trifluoroacetic acid). Protein was collected, run through a rotovap to remove acetonitrile, snap
frozen and lyophilized. All stages of purification were monitored by SDS-PAGE gel.
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4.2.3: COACERVATION STUDIES
Coacervation studies were conducted using an HP 8452A diode array photospectrometer
running Olis Spectral Works equipped with a peltier temperature controller (Quantum Northwest
TC125). Protein concentrations were determined using extinction coefficient calculations at an
absorbance of 280 nm, with the predicted coefficient 13980 M-1cm-1. Lyophilized protein was
dissolved in either coacervation buffer, 50mM Tris, 1.5M NaCl, 1mM CaCl2 pH7.5, or a listed
variation utilized to test the effect of the change.
Samples were placed into a 1.5mL quartz cuvette and placed in the sample holder and
equilibrated at initial temperature for at least five minutes. The temperature was then increased at
1˚C/min with stirring. Scattering was monitored at 440nm. Upon completion of the temperature
titration, samples were cooled to 10˚ C and centrifuged at 13,200rpm to separate coacervated
protein that did not return to solution. This material was washed with deionized water and stored
for solid-state NMR.
Optical microscopy samples were obtained during coacervation studies by removing
50uL of solution every five degrees and immediately placing the cover slide and sealing the slide
with nail polish. Images were collected on a Zeiss LSM710.
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4.2.4: THIOREDOXIN PURIFICATION
Protein was initially grown in E. coli following the procedure listed above in
Appendix3.3.9: TPP Media Growing Instructions. Briefly, E. coli strain NiCO21 contained the
Pet32a(+) vector that had the plasmid and DNA was grown in LB and then TPP against
ampicillin. The E. coli was induced to produce the protein and after four hours was spun down.
The pellet was resuspended in wash buffer and lyced open. The lyced solution was spun down
and separated into solid and supernatant. The solid was then resuspended in high concentration
urea to denature any protein remaining. The supernatant had 3 M salt added to the solution and
brought to room temperature. This temperature and salt increase coacervated the 20’_2123_24’_21-23_24’. The supernatant was then spun down at 13,200 rpm for 10 minutes at room
temperature. This supernatant was decanted. The solid was resuspended in low concentration
imidazole buffer and chilled. A SDS-PAGE gel was run on the initial lyced debris in urea, the
lyced supernatant with 3 M salt, the supernatant of the room temperature spin, and the solid
resultant from the room temperature spin.
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4.2.5: SOLUTION NMR
4.2.5.1: 1D SOLUTION NMR

One dimensional solution NMR was conducted at Louisville University using a Varian
800 MHz. Data was collected at 25˚C. Protein concentration was approximately 300uM in 10%
D2O in a 25mM phosphate, 25mM KCl buffer at pH 7.0. Water gating was used to suppress the
water signal.
4.2.5.2: 2D SOLUTION NMR
Two dimensional solution NMR data was collected at both Louisville University on a
Varian 700 with cryoprobe and Varian 800 with cryoprobe and at City College of NY (CCNY)
on a Varian 700 with cryoprobe. Data collected at Louisville came from a sample with protein
concentration of approximately 300 uM, in 10% D2O at 25˚C in 25 mM phosphate, 25 mM KCl
buffer at pH 7.0 and 5.9. The experiments completed were NHSQC, TOCSY-HSQC and
CHSQC.
Data collected at CCNY came from samples with approximate protein concentrations of
800 uM unless specified with the data. The samples contained 10% D2O. Buffers and
temperatures were varied and are listed with each data set. The experiments completed were
NHSQC.
4.2.5.3: 3D SOLUTION NMR
Three dimensional solution NMR data was collected at Louisville University on a Varian
700 with cryoprobe and Varian 800 with cryoprobe. The protein concentration was
approximately 300 uM in 10% D2O at 25˚C in 25 mM phosphate, 25 mM KCl buffer at pH 7.0
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and 5.9. The initial experiments completed were HNCA, CBCANH, CBCACONH, HNCO, and
HNCOCA.
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4.3: RESULTS AND DISCUSSION

4.3.1 COACERVATION STUDIES
To determine whether the designed protein functioned in the same fashion as native
tropoelastin, coacervation assays were completed to demonstrate that the protein self-aggregated
when the temperature was increased above the critical temperature, if the salt concentration was
substantially increased, or if the pH was varied. As seen in Figure 18, coacervation did occur
when heated above a critical temperature of coacervation and the particles that formed were large
enough to be seen by the naked eye.

FIGURE 18: TEMPERATURE COACERVATION OF 20'_21-23_24'_21-23_24'
20’_21-23_24’_21-23_24’ was heated 1˚C/min to 80˚C and gently stirred.
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Once it was confirmed the protein coacervated, characterization of self-aggregation was
necessary. Coacervation was quantified using the scattering at 440 nm in the UV-Vis
spectrophotometer. The critical temperature of the coacervation did follow trends demonstrated
by previous research, wherein adding salt reduced the heat required to self-aggregate. This result
can be seen in Figure 19 when the same concentration of protein was assayed multiple times with
varying amounts of salt. As the temperature was increased, self-aggregation occurred at lower
temperatures for higher concentrations of salt.
The coacervation did not appear to be dependent upon the rate of stirring. However, as
evidenced by the black 0 M salt trial in Figure 19, when the stirring rate was not sufficient, the
particles became heavy enough to fall out of suspension and rest on the bottom of the container,
yielding a decrease in scattering and a break in the coacervation curve.
0.6

Coacervation of 20'_21-23_24'_21-23_24', pH 6.0, 25 uM, 50 mM Tris, 1 mM CaCl2
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FIGURE 19: SALT DEPENDENT COACERVATION OF 20'_21-23_24'_21-23_24'
The coacervation study utilized 50 mM Tris Buffer with 1 mM CaCl2, with 25 uM samples
varying NaCl concentration. All samples had temperature increased at 1˚C/min with gentle
stirring.
44

Additionally, reducing the pH of the protein lowered the critical temperature of
coacervation, as can be seen in Figure 20. While scattering of the same concentration of protein
with the same salt and buffer constituents appeared to approach the same asymptote, the lower
pH sample began to coacervate sooner with more scattering detected at lower temperatures.
Contrasting this is the higher pH sample that had nearly no scattering detected until five degrees
from maximal scattering.
One feature of the coacervation scattering assays is the baseline. While it can be seen in
Figure 20, it is more prominent in the 1.5 M NaCl trial in Figure 19. Even at the lowest
temperatures of the assay, some scattering is detected and prevents a common baseline as a
result. This initial scattering is worth noting and therefore not removed as background.
Coacervation of 20/24/24, 1.5M NaCl, 25uM, 50mM Tris, 1mM CaCl2
1.2
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FIGURE 20: PH DEPENDENT COACERVATION OF 20'_21-23_24'_21-23_24'
The coacervation study used 50mM Tris Buffer, 1.5M NaCl, and 1mM CaCl2 as a constant buffer,
varying the pH between trials with both trials increasing the temperature one degree per minute with
gentle stirring.
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Coacervation critical temperature variations have been demonstrated by temperature
modulation, pH modulation and salt concentration. It was therefore hypothesized that by solely
increasing the salt concentration at a fixed temperature the critical temperature could be shifted
to the point of coacervation. Figure 21 demonstrates the successful implementation of this
hypothesis. A salt solution was titrated into the protein solution at 48ᵒ C until the protein
coacervated. Salt solution continued to be added in order to observe the effects upon scattering
after coacervation, as well. Approximately 2 M salt concentration with a pH 6 at 48˚C is the peak
of coacervation. Beyond this concentration of salt the scattering signal began to decrease,
possibly because the ionic strength of the solution was interfering with additional selfaggregation, or even protein folding.

Coacervation varying NaCl 48C, 25uM, pH 6.0

440 nm

0.4

0.2

0
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2 2.25 2.5 2.75
NaCl(M)
FIGURE 21: SALT COACERVATION ASSAY
25 uM protein in 50 mM Tris, 1mM CaCl2 at pH 6.0 was warmed to 48˚C and then aliquots of
NaCl were added, 100 mM at a time and stirred. Scattering was observed at 440 nm.
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During a temperature coacervation assay, 50 uL samples were removed from the overall
sample and sealed on microscope slides. The samples were then imaged using a confocal
microscope using 500 times zoom. Samples below the critical temperature had very little
structure visible at all, as is seen in Figure 22A where the sample was removed at 5˚C. In
contrast, samples above the critical temperature had large formations, as is seen in Figure 22B.
The large formations visible above critical temperature appear to be particle-like and not fibers,
while tropoelastin cross-links to form elastin in the shape of fibers.
The microscope’s resolution limit was a determining factor in this assay, as it was very
difficult to visualize any particles smaller than 10 um. As mentioned earlier, the size of the
protein can be approximated to be roughly 5-10 nm. Therefore, the smallest self-aggregation
would be 10-20 nm, well below the threshold of the microscope. Scattering of the smallest selfaggregated proteins can be visible with Rayleigh scattering while the particles detected with the
confocal microscope would be well beyond the size limit of Rayleigh scattering, following Mie
scattering theory instead.

FIGURE 22: IMAGED COACERVATION 5˚C AND 85˚C SAMPLE
Confocal microscopy images of 25 uM 20’_21-23_24’_21-23_24’ samples in 50 uM Tris, 1 mM
CaCl2 at pH 6.0 with 1 M NaCl. A) Very little coacervation was detected at 5C, with most
protein not visible within the microscope range. The scale is 20 um. B) Coacervation was easily
visible within the range of the microscope, with larger structures of various sizes forming.
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One of the concerns was the non-reversibility of the construct upon coacervation. It is
known that an increase in temperature can induce non-reversible protein aggregation.51 To
demonstrate the functionality of 20’_21-23_24’_21-23_24’, the protein was cross-linked with
0.02% gluteraldehyde for eighteen hours and imaged using a confocal microscope. Long strands
of cross-linked protein, resembling elastin, were visible, as is seen in Figure 23.

FIGURE 23: CROSSLINKED 20'_21-23_24'_21-23_24'
Cold 40 uM protein had 0.02% gluteraldehyde added. Sample was then placed in a hot water
bath with gentle agitation for 18 hours. Subsequently 50 uL was sealed on microscope slide and
imaged with confocal microscope.
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4.3.2 SOLUTION NMR
Solution NMR was conducted to ascertain structural information on the designed
protein. The first experiment completed on the protein was 1D NMR to obtain a baseline for all
future experiments. This can be seen in
Figure 24. The aliphatic protons can be seen in the 0-2 ppm region, the alpha protons in the 34 ppm region, and the amide protons 7-8.5 ppm with two very small peaks at 10 ppm, possibly
representing the two tryptophan amino acids.

FIGURE 24: 1D NMR SPECTRA OF 20'_21-23_24'_21-23_24'
The spectrum was collected on a Varian 700 with protein in 25 mM Phosphate, 25 mM
Potassium Chloride buffer, at pH 7.0 at 25˚C.
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Initial NMR experiments were undertaken prior to HPLC purification of the protein. It
was hypothesized that the HPLC step of purification would modify the spectra obtained from
NMR. As a result, pre and post HPLC data was connected to determine any potential differences
that may have resulted from the removal of the low concentration of contaminants that remained
following standard purification. The primary observation made from Figure 25 is slight chemical
shift following purification. However, this could be the result of the spectrometer being utilized
on different days with potential temperature fluctuations. Aside from the slight up-field chemical
shift, many peaks appear much more distinct. However, the concentration following HPLC was
significantly higher, and as a result, peaks were able to be distinguished much more easily from
background. Therefore, it appears differences from purification are minimal.

FIGURE 25: NHSQC OF 20'_21-23_24'_21-23_24'
Protein was in 50 mM Phosphate buffer at pH 5.9 at 25˚C. The black sample is prior to HPLC
purification and approximately 300 uM, and the red overlay is the protein after HPLC
purification and approximately 800 uM.
50

After investigating the effects of small concentrations of contaminations, the effects of
pH was investigated. The initial pH ran was 7.0, close to that of physiological conditions, which
were believed to be ideal for tropoelastin. It was compared with pH 5.9, which was believed to
yield higher quality NMR spectra. As seen in the coacervation studies, a decrease in pH does
allow for self-aggregation at lower temperatures, but with the temperature of the sample
maintained around 25°C, coacervation effects were kept to a minimum.
While the red pH 5.9 spectra comes from a much more concentrated sample, it actually
appears to have fewer peaks in some regions of the NHSQC. In particular, the down-field 15N
region, especially around 1H 7.75 ppm appears to have more overlapping peaks. This could be
indicative of the protein being more molten globular and less folded. There are some areas where
it appears that there are more signals with the lower pH, but this may be the result of a higher
concentration and better signal to noise.

FIGURE 26: NHSQC OF 20'_21-23_24'_21-23_24'
The protein was in 25 mM Phosphate, 25 mM Potassium Chloride buffer at 25˚C. The black 300
uM sample is at pH 7.0, the red 800 uM sample is at pH 5.9.
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Many of the coacervation assays in the literature were completed with 1 mM CaCl2. To
determine whether this addition interacts with the protein, an NMR experiment was performed
prior to calcium chloride being added then an excess was added and the sample wre-evaluated.
As can be seen in did not affect the NMR spectra.

Figure 27 there was a slight down-field shift after the addition of the calcium chloride, but no
other appreciable differences were detected. This result indicates that while the calcium chloride
was used in the coacervation buffer, it did not affect the NMR spectra.
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FIGURE 27: NHSQC OF 20'_21-23_24'_21-23_24'
Protein was in 50 mM Phosphate Buffer pH 5.9 at 10˚C. The black sample does not contain
CaCl2. The red sample contains 1 mM CaCl2. Approximate protein concentration was 750 uM.

53

Another hypothesis tested was the possibility that the protein underwent conformational
changes as it approached the critical temperature of coacervation. To test this hypothesis a
temperature titration NHSQC was run. It is well known that as temperature increases there is a
corresponding up-field 1H shift. This phenomenon helps to minimize peak overlap by all peaks
shifting to the right as the temperature increases. However, there were approximately five peaks
whose 15N peaks did not follow the trend of shifting up-field. Additionally, not all up-field shifts
appeared to happen at the same rate. This is believed to be the result of hydrogen bonds
interacting differently in their surroundings as presented by Cordier and Grzesiek in 2002.52

FIGURE 28: NHSQC OF 20'_21-23_24'_21-23_24’
Sample was in 50 mM Phosphate Buffer, pH 5.9. A temperature titration was completed with
black at 15˚C, violet at 20˚C, sea green at 25˚C, peach at 30˚C, orange at 35˚C and red at 40˚C.
After each dataset was collected, the instrument temperature was increased, then given five
minutes additional time to equilibrate. Approximate protein concentration was 880 uM.
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Peak intensity as a function of temperature had the potential to produce results that
would have indicated the concentration of sampled protein had decreased because the protein
aggregated. However, as seen in Figure 29, variations between different peaks are so wide that
there is no discernable trend. This is counter-intuitive because it was visible to the naked eye that
as the temperature increased, the protein coacervated, in turn, reducing the concentration in
solution. One possible explanation for the lack of decreasing trend could be the relative
concentration differences. The NMR sample was very concentrated, which while producing very
clear spectra, may have made it insensitive to small fluctuations in the concentration.

FIGURE 29: NHSQC PEAK INTENSITYOF 20’_21-23_24’_21-23_24’
The peak intensity was plotted as a function of temperature. Protein was in 50 mM Phosphate
Buffer, pH 5.9. Approximate protein concentration was 880 uM. The NHSQC spectra on the
right has the various peaks circled to indicate where on the spectra the intensity peaks
originate.
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Three dimensional NMR experiments HNCO, HN(CA)CO, CBCANH, and
CBCACONH were conducted on 20’_21-23_24’_21-23_24’ in an attempt to completely assign
the backbone of the protein. However, this proved impossible due to the molten globular
conformation the protein adopted. The HNCO shows approximately 60 peaks. However, the
protein contains 182 amino acids, and with only 21 prolines, there should be approximately 161
peaks without overlapping. The fact that roughly 100 peaks are missing is indicative of the
molten globular conformation. When investigated more closely, it can be recognized that one
repeat in 20’, one repeat of 24’ and one cross-linking domain can be approximated by the 60
peaks visible on the HNCO. This section of the backbone was assigned, but it is not possible to
determine which segment of the 20’ or 24’ domains or which cross-linking domain is being seen.
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4.3.3: THIOREDOXIN PURIFICATION
In determining if the elastin-like protein functioned as a typical elastin-like protein, it was
used to purify thioredoxin. In many laboratories a thioredoxin His6 tag is appended to the desired
protein. In purifying 20’_21-23_24’_21-23_24’ a thioredoxin tag was appended with a TEV cleavage
site. This created a nickel affinity that aided in purification. However, the construct could also be
looked at in a different light, wherein the elastin-like protein was added to the thioredoxin tag.
Now the unique self-binding affinity of the elastin-like protein at high temperatures can be utilized
to separate it from other soluble proteins. Figure 30 demonstrates the entire process of

thioredoxin purification prior to the removal of the elastin-like protein tag. The most telling
information appears in lanes 2 and 13. Lane 2 is a sampling of all proteins that were within the
lyced E. coli supernatant. Lane 13 is all solid precipitant from Lane 2 that subsequently went
back into suspension. The key features are the increase in concentration of the sample and the
disappearance of the band immediately above 12 kDa. Purification protocols using elastin-like
proteins for separation of target proteins often use coacervation multiple times, whereas the
results in Error! Reference source not found. are after only one coacervation and suspension.
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FIGURE 30: THIOREDOXIN PURIFICATION
A. Lane 1 is the molecular weight marker, lanes 2-4 are the lyced supernatant before adding salt
and raising temperature, lane 2 is full concentration, lane 3 diluted in half, lane 4 is diluted to
25%. Lanes 5-7 are the lyced debris resuspended in 8 M urea wash buffer. Lane 5 is full
concentration (but much of the sample did not transfer to the gel due to aggregation in the
pipette. Lane 6 is 50% and lane 7 is 25% concentration. Lanes 8-10 is the supernatant after
centrifugation of the high temperature salt solution. Lane 8 is 25% concentration, lane 9 is 50%
and lane 10 is full concentration. Lanes 11-13 are the high temperature solid resuspended in cold
wash buffer. Lane 11 is 25% lane 12 is 50% and lane 13 is full concentration.
B. Lanes 1, 2, and 13 are shown side-by-side to demonstrate the before and after purification.
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4.4: CONCLUSIONS
By coacervating as the temperature increases, this work demonstrates that the designed
elastin-like protein 20’_21-23_24’_21-23_24’ behaves similarly to native tropoelastin.
Additionally, the protein’s self-aggregation is also dependent upon the ionic strength of the salt
concentration, the pH, the protein concentration, and the choice of buffer-- which is expected due
to native tropoelastin’s similar coacervation profiles.
Preliminary cross-linking work indicates that the de novo elastin does cross-link, further
indicating the functionality of the protein. Images showe fiber-like structures beyond the basic
particle formation seen during coacervation.
Nuclear Magnetic Resonance spectroscopy indicates that the ideal pH for the designed
protein is near physiological conditions, provided the sample concentration is high.
Additionally, the calcium chloride utilized in the coacervation buffer is not necessary in the
NMR samples because there was no negligible difference between samples with and without the
calcium chloride. Salt titrations were not carried out due to the tendency for high ionic strength
to yield poor NMR results. However temperature titrations were completed in order to look for
conformational changes as the protein approached coacervation. A few small changes were
observed, but there did not appear to be significant changes in folding.
Furthermore, three dimensional NMR was used to assign resonances which correspond to
different parts of the protein, specifically one GVGGV repeat of 20’, one cross-linking domain,
and one GVGVA repeat of 24’. The molten globular nature of the de novo protein constrains
the other chemical shifts to be either overlapping with the identified or missing due to relaxation
or exchange.
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CHAPTER 5: FUTURE DIRECTIONS
5.1: MODIFICATIONS OF MODEL PROTEINS
5.1.1: 20’_21-23’_24’_21-23’_24’
Initial modifications of 20’_21-23_24’_21-23_24’ have been completed and synthesized.
These new designs must be studied to determine the effects of the changes implemented. From
these studies, it will be possible to design a possible third generation of small elastin-like
proteins to test the conclusions drawn from the initial modifications.
Future studies on the modified protein motif should begin with experiments on 20’_2123’_24’_21-23’_24’. In comparing this protein with the original 20’_21-23_24’_21-23_24’, it is
possible to explicitly determine the effects of varying the cross-linking domain. The studies to be
completed include temperature, salt, pH and concentration coacervation assays, CD and NMR.
If the coacervation data shows a decrease in coacervation temperature, those results
would be indicative of an increase in ease of self-aggregation. This could mean the designed
cross-linking domain 21-23’ is more solvent-exposed or active than the original 21-23 domain.
Additionally, the coacervation assay will indicate if the self-binding affinity decreased.
The original protein had such a high self-binding affinity that coacervation was
permanent, a phenomenon highly uncommon in elastin-like proteins. The second half of the
coacervation assay of the new protein yielded a basic indication of the level of self-binding
affinity. As the temperature of the sample was decreased, the original protein showed no
indications of disassociation. The new protein’s coacervation assay could show a decrease in
scattering as the temperature is decreased. This behavior would be consistent with other elastinlike proteins that go back into solution below the critical temperature of coacervation.
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Additionally, NHSQC 2D solution NMR on a sample with identical conditions to those
the original protein was in when data was collected, which is listed with each figure, should be
collected. The NHSQC spectra collected can be used as a basis to determine folding of the
protein. The original protein contains 182 amino acids; the NHSQC of the original protein
contained approximately 60 unique chemical shift peaks. The protein contains 21 proline amino
acids that do not exhibit a peak on a NHSQC; if the protein were completely folded, there should
be 161 peaks. The fact that over 100 amino acid peaks were not visible on the NHSQC is
indicative of the chemical shifts overlapping or loss due to exchange. If the new protein is folded
more, it will have additional peaks on the NSHQC compared to the original. If enough peaks are
present, it may be possible to determine the structure of the designed protein with 3D NMR
experiments.

5.1.2: 20’_20’_21-23_24’_21-23_24’_24’
The second protein that should be studied is 20’_20’_21-23_24’_21-23_24’_24’. This
design attaches an addition hydrophobic region to each end of the original de novo protein. This
protein should be characterized in the same fashion as the original protein, utilizing coacervation
assays, circular dichroism and solution NMR. If the coacervation studies indicate a lowering of
the critical temperature for self-aggregation, then that would indicate that a larger elastin-like
protein is more stable than a smaller one. The fact that the number of cross-linking domains
remained constant should help support the hypothesis that the number of hydrophobic domains is
the driving force behind the lowering of the critical temperature rather than the ability for
additional cross-linking.
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This larger protein may introduce additional difficulties in NMR, as the larger protein, in
part, will have more relaxation effects because the tumbling rate will be slower. This will cause
line broadening. This can be compensated for to an extent by additional scans, which adds time
to the experiment; and the longer the protein is in the equipment, the more opportunity for
degradation, which will also decrease the quality of the data. These difficulties may make CD a
more useful source for the secondary structure of the protein.

5.1.3: 24’_21-23_24’_21-23_24’_21-23_24’
The third protein that has been designed focuses on the 24’ hydrophobic domain. This
protein will also need to be tested against the same experiments run on the original 20’_2123_24’_21-23_24’ protein. Coacervation studies varying concentration, pH, salt and temperature
will all provide insights into this protein. Comparing the critical temperature of coacervation as
well as the salt concentration will allow for hypotheses regarding the functionality of the crosslinking and elasticity of the resulting mini-elastin. Circular dichroism and NHSQC will help to
determine the secondary structure of the protein to determine if the repeating motif allowed for a
unique folded conformation, or if the protein is molten-globular or unfolded.
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5.2: CROSS-LINKING STUDIES
Very initial cross-linking data was collected, demonstrating that the model proteins were
functionally viable for cross-linking. Systematic studies of cross-linking are a next logical step.
One variable that can be tested is the type of cross-linking chemical. Natural elastin uses lysyl
oxidase for cross-linking, which would be the obvious choice to investigate; however, using
gluteraldehyde, data has also been collected to successfully cross-link. While gluteraldehyde
would most likely have more immunological interactions, a comparison between the two crosslinking agents would be worthwhile.
A second variable to investigate is cross-linking conditions. Initial data was collected
with 0.02% gluteraldehyde added to protein solution and the solution was warmed and gently
agitated for 18 hours. The amount of cross-linking agent is a variable to consider, as well as the
temperature of the solution, the length of time allowed for cross-linking, and the amount of
agitation. Additionally, varying the protein concentration is a condition that merits investigation.
This would be different than varying the concentration of the cross-linking agent because the
self-aggregation of the protein is dependent upon protein concentration and the self-aggregation
is required for cross-linking.
Assays of the cross-linking also needed to be investigated. Use of the confocal
microscope gave a qualitative result of successful cross-linking, but there was little quantitative
data derived. Data that could be collected in the future would be average density, thickness, and
length of cross-linked strands. Additionally, cross-linking forms large particles, so the scattering
assays used for coacervation could yield results on speed of cross-linking. Another method to
test cross-linking is via the elasticity studies described in the next section.
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5.3: ELASTICITY STUDIES
Collaborators will utilize Atomic Force Microscopy (AFM) to study the elasticity of the
proteins. The AFM uses a very fine tip and deflection of the tip is recorded and translated into
position signal. Traditionally, as a tip scans across a surface, it is able to record grooves and
peaks; and with systematic scans along a sample, it can recreate the surface topology. In this
application of the AFM, the non-cross-linked coacervated protein will “stick” to the tip of the
AFM and the machine will slowly pull back the tip; the resistance will be indicative of the
stretch of the protein. When the resistance stops or significantly decreases, the protein has
stretched to the point where it snapped or its bond with the tip or base surface broke. This
experiment will be repeated for many hours with the results represented in a histogram that will
ideally have one narrow peak indicative of the elasticity of the protein.
Upon completion of the experiment with non-cross-linked coacervated protein, it will be
repeated with cross-linked protein. The elasticity of the cross-linked protein should be
substantially larger. This experiment will be very valuable in determining optimal cross-linking
conditions as well as providing insights into the variations of the different protein constructs that
have been designed to probe the functionality of the hydrophobic domains and the cross-linking
domains.
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5.4: SOLID-STATE NMR
Solid-state NMR (SSNMR) can be used to study the self-aggregated cross-linked protein
as opposed to solution NMR, which studies the protein prior to self-aggregation. The SSNMR
samples are not in solution; rather they are spun down and dried. This method can allow for
studying the solids that can actually make the solution NMR signals less ideal. The primary
difficulty with SSNMR in this case is the quantity of protein needed for the experiment.
Samples that are run in SSNMR should be prepared in identical fashion, so a great deal of
20’_21-23_24’_21-23_24’ should be purified initially and prepared in multiple fashions to find
the ideal conditions for future proteins to be prepared for SSNMR. Once solid-state samples have
been prepared, they can be run to help clarify the structure of the protein utilizing the chemical
shifts.

5.5 DIFFERENTIAL SCANNING CALORIMETRY
Another method to study the self-aggregated and cross-linked proteins is with
Differential Scanning Calorimetry (DSC). In this experiment, 50 uL of sample would be placed
in a cold pan and held at 5˚C until equilibrated. It is then heated and the difference of energy
needed to heat the sample compared to the reference sample would be recorded. The parameters
used in preparing the 20’_21-23_24’_21-23_24’ sample for DSC would need to be tested and
varied initially so that once the optimal conditions are found, they can be repeated for additional
proteins to be tested via DSC. Some parameters to investigate would be pH, salt concentration,
protein concentration, and cross-linking parameters.
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5.6 CIRCULAR DICHROISM
Circular dichroism is scheduled to be completed on 20’_21-23_24’_21-23_24’ in the
immediate future. There are a few parameters that can be modified in order to explore the
secondary structure of the protein. A temperature titration using CD would yield very interesting
results showing whether the protein folded with the increase of temperature as it approached the
coacervation critical temperature. Varying the buffer, pH and salt concentration and running
additional temperature titrations has the potential to yield further interesting results.
Circular dichroism on 20’_21-23’_24’_21-23’_24’ would be completed after the results
of 20’_21-23_24’_21-23_24’ have been analyzed. The conditions for the new CD temperature
titrations would need to be identical to those of the initial titration. This parameter would allow
for clear comparison between the two to determine whether or not the modification of the 21-23
cross-linking domain improved the secondary structure. Additionally, by waiting until the
analysis of the data for 20’_21-23_24’_21-23_24’, it would be possible to determine the ideal
parameters to run the subsequent experiments, thereby reducing the number of CD titrations on
the future generations of proteins.
The next protein to have CD temperature titrations would be 20’_20’_21-23_24’_2123_24’_24’. This protein would also utilize the same conditions for the temperature titrations as
the original protein for ease of comparison. If the secondary structure improves with the
modifications made to this protein, it would indicate that the adding of additional hydrophobic
domains improved the ability to fold, since that was the only modification.
The final protein on which to run CD temperature titrations would be 24’_21-23_24’_2123_24’_21-23_24’. This experiment would also utilize the same conditions as the initial protein
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to allow for comparison. If the secondary structure is less molten-globular than the initial protein,
it will warrant further investigations by creating additional proteins. The secondary structure may
have improved because this protein has three cross-linking domains as opposed to two, which the
previous proteins have. It is also possible that the protein structure improved because only the
24’ hydrophobic domain was utilized while the 20’ hydrophobic domain was omitted. This
could be studied by creating two additional proteins: 24’_21-23_24’_21-23_24’ and 20’_2123_20’_21-23_20’_21-23_20’. The first new protein is identical to the original protein with the
exception that the 20’ hydrophobic domain has been replaced by the 24’ hydrophobic domain.
The second construct is identical to the final in the first series of revisions except each of the 24’
hydrophobic domains has been replaced by the 20’ hydrophobic domain. The secondary
structure of these proteins would help to further deduce whether improvements were due to
additional cross-linking domains or if the improvements were the result of the 24’ hydrophobic
domain.
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APPENDIX 2: LABORATORY EXPERIMENTAL PROCEDURES

2.1: NITRIC OXIDE ENZYMATIC ACTIVITY
Protein nitric oxide (NO) affinity can be characterized where enzymatic rates can be
investigated. Two controls can be used-- horse heart myoglobin (Mb) and flavohemoglobin
(fHb).
The NO enzymatic rate investigation utilizes a combination of Gardner53 and Hargrove54
procedures. Commercial NO gas arrives as NOx and must be passed through sodium hydroxide
to remove unwanted forms, leaving a more pure NO.55 The NO is blown over the 0.1 M
potassium phosphate pH 7.4 buffer in a gas tight container while being stirred for at least ten
minutes. The saturated buffer can be stored at 4°C for approximately one month,56 but for
optimal results due to leaks, this should be made fresh or re-saturated for each trial. The
concentration of the saturated solution is temperature dependent upon initial saturation. At 25°C,
the concentration is approximately 3 mM.56, 57
A World Precision Instruments NO probe is used to determine the NO concentration in a
1-3 mL sample, provided the concentration is within the linear range of the detector. The linear
range is determined by calibrating the probe with increasing injections of known amounts of NO
and creating a response curve.58 The linear region of the response curve is the functional region
for the probe. Current experiments are being conducted with a probe that has a linear response
from below 5 uM to 30 uM and a second probe which has a linear response from 20uM to more
than 80 uM, as seen in Figure 31.
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FIGURE 31: LINEAR RESPONSE REGION FOR NO PROBES
Black points represent the calibration of the high NO concentration probe with the black solid
line representing the fit approximated for the probe. Note the discrepancy at concentrations
below 20 uM. White points represent the calibration of the low NO concentration probe with the
dotted line representing the fit approximated for the probe. Note the discrepancy above 40 uM.

Calibration of the NO and oxygen probes follows the guidelines set forth within ISONOP manual by World Precision Instruments.58 The oxygen probe is calibrated by first
determining the amperage output from the probe in 0.1 M phosphate buffered saline (PBS)
solution with atmospheric oxygen present (21%). Then the PBS is saturated with 100% oxygen
for more than five minutes and the amperage output is recorded. Finally the PBS is saturated
with 100% nitrogen for more than five minutes and the amperage output is recorded for 0%
oxygen. The points are then plotted and the equation of the line is used to convert the amperage
output to percent oxygen in the sample.
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Calibration of the NO probe is completed in 0.1 M potassium phosphate buffer with a pH
of 7.4. With 0% NO in the 1 mL sample, baseline amperage is recorded. Then a small aliquot of
NO is added, often 5 uM. Once the amperage plateaus, the value is recorded. Double the amount
of NO is then added, usually 10 uM. Once the amperage plateaus, the value is recorded and a
third aliquot of NO is added, usually 20 uM. The amperage is recorded once it plateaus. The
additions are added via a gas-tight Hamiltonian 10 uL syringe as quickly as possible, as the NO
within the sample is being converted into other forms of NOx and the amperage will begin to
decrease quickly after plateauing. With the four values of amperage at various NO
concentrations, a response curve can be constructed to convert the amperage to molar
concentration of gas present in the sample. A sample curve and fit is presented in Figure 32.

FIGURE 32: NITRIC OXIDE PROBE CALIBRATION
Calibration points for NO are at 0, 1.25, 2.5, 5, 10 and 20 uM concentration.
The gradient and intercept are used to calculate the conversion between nA to uM of NO.
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A key feature of the probes is that they are temperature dependent and also dependent
upon the stirring rate. Prior to calibration, to ensure consistency throughout experiments, the
reaction chamber is placed in a water bath that is maintained at 25°C and the stirring rate is set at
600 rpm. Neither setting is adjusted for the remainder of the experiment.
NO consumption experiments are completed in a 1 mL volume. The volume contains 3
mM glucose-6-phosphate (G6P), 60 uM nicotinamide adenine dinucleotide phosphate (NADP+),
1 uM ferrodoxin-NADP reductase (FdR), 0.7 units of glucose-6-phosphate dehydrogenase
(G6PD), 5-20 uM protein, and 2.5-25 uM NO, with the remainder of the solution is potassium
phosphate buffer, with a pH of 7.4. The above concentrations are variations of the set-up
presented by Hargrove’s group54. It has been concluded that the NADP+ needs to be prepared
fresh daily, as use of older supplies gives inconsistent results (figures omitted). All solutions
should be kept on ice or refrigerated when not in use. Proteins tested so far include Mb, fHb and
de-novo designed HHHH. The HHHH and fHb require heme added to the protein to create a
complex. However, heme is stored in dimethyl sulfoxide (DMSO) which is an organic solvent
that destroys the membrane and probe. Thus, upon creating a complex of heme and protein, the
DMSO must be dialyzed out. The HHHH complex could be put over a desalting column;
however the fHb does not travel through the column unaffected. It is hypothesized that the
protein breaks into two domains; the flavin traveling more slowly through the column. As a
result, dialysis is the optimal method for fHb, and the HHHH complex is treated in the same
fashion.
Maintaining constant protein concentration and varying the amount of NO added
completes consumption experiments. This varies the amount of buffer, but all other solutions
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remain constant. The G6P, NADP+, FdR, protein, and buffer are added to the reaction chamber
and degassed until the oxygen concentration is approximately 4% as determined from the oxygen
sensor. The rationale for 4% oxygen is that the reaction of FdR and NADP+ requires a small
amount of oxygen, but NO reacts with oxygen. Thus, it is essential to minimize the amount
present to allow the NO to be consumed by the protein rather than the oxygen.53 The aliquot of
NO is added, the amperage spikes to indicate the presence of NO, and then quickly decays as the
protein reacts with it. The initial decay slope is the initial velocity, which is used in enzymatic
calculations including the Michaelis-Menten equation and Lineweaver-Burke Plot for the Km, the
Michaelis constant, and Kcat the catalysis rate constant. Figure 33 is an example response curve
of 20uM NO being added to 10uM Mb. This is seen with the red curve, and 10uM NO is added
to buffer as seen by the black curve.

FIGURE 33: NITRIC OXIDE ENZYMATIC ACTIVITY
The black curve is the background decay rate of NO in buffer, to determine the rate that NO is
converted to NOx, where 10 uM of NO is injected to the sample that does not contain the studied
protein. The red curve is indicative of 20 uM of NO added to 10 uM Mb. The initial slope is
significantly sharper than the background black curve.
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Important lessons learned from this set-up include NO’s ability to corrode copper. As a
result, all tubing, needles and fittings need to be stainless steel, plastic or rubber. Rubber will
become brittle more quickly in the presence of NO, and as a result it is recommended to replace
stoppers weekly. Additionally, cleaning the reaction chamber should be done with care to reduce
the probability of the chamber becoming brittle and scratching and absorbing proteins.
Quick cleaning of the chamber between runs can be accomplished using a long blunted
needle to withdraw the maximal amount of liquid and rinsing several times with de-ionized
water. Thorough cleaning is needed at the end of the day or when switching between protein
samples. To thoroughly clean the reaction chamber, first withdraw the maximal amount of liquid
using a blunted needle. Next, add approximately 1 mL of 1:256 diluted in water Coverage Plus
NPD cleaner. Allow solution to stir with the stir bar for at least two minutes, then using the
blunted needle, withdraw as much liquid as possible. Rinse the reaction chamber more than three
times to ensure the cleaner is removed. Avoid using ethanol as much as possible, as this will
make the plastic even more brittle.
Additionally, the sodium hydroxide bubbler that the NO is passed through will lose
efficacy over time. It is recommended to replace the 1 M sodium hydroxide solution bi-weekly to
ensure purity of NO. To replace the solution, the first and most important step is to vent the gas
train with nitrogen before removing the bubbler from the gas line. If unfamiliar with the NO
regulator that has the option to vent with nitrogen read the manual, but a brief and
incomprehensive summary is to switch the top gas valve to off so NO will not leave the regulator
or permit nitrogen to back in to the NO tank. Next, turn on the nitrogen tank then switch the
valve on the nitrogen tank to go into the NO regulator. Then turn the NO regulator valve to allow
nitrogen to vent through it, in effect purging all lines with nitrogen and removing all NO. Once
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nitrogen has run through the system for at least ten minutes, the nitrogen can be stopped and the
bubbler can be removed from the gas train. Pour out old solution while still in the hood, taking
care not to inhale the vapors or allow the liquid to contact skin, as in addition to be being 1 M
sodium hydroxide, it also contains various forms of NOx. Once the bubbler is empty, rinse it with
ethanol and de-ionized water. Refill the bubbler with 40 mL of 1 M sodium hydroxide and
replace it in the gas train. Prime the gas line with nitrogen for an additional ten minutes before
switching over to NO by reversing the process of allowing the nitrogen to flow through the
regulator. It is critically important to close the valve to the nitrogen line before opening the NO,
as it will be damaging for the lines if NO enters into the lines connecting the nitrogen tank,
especially when it is time to replace the nitrogen tank.
If at any time brown fumes are visible outside the hood, NO is leaking from the
container. Quickly try to stop the leak by turning off the tank. Then evacuate and ventilate the
room. Contact emergency personnel if warranted. Signs of exposure to NO may include feeling
faint, burning sensations from inhalation, and rapid heartbeat. The rapid heartbeat may last many
hours after exposure.
To run the experiment, two pieces of software are used in Koder Lab. The first piece of
software is for an MCQ Instruments three-channel gas blender. Open the software “Gas Mixer
Manager”. In order to use the software, you must click on the “Connect Device” button. Two
channels have been set up for use: nitrogen and oxygen. Nitrogen percentage is determined by
changing the percentage of oxygen from 0-100%; thus nitrogen will be 100-0%.
The second piece of software is for the WPI gas sensors. To run the hardware, open the
software “LabScribe2”. This software can record up to four channels. To vary the display,
change units, or change the scale, open the Edit drop-down menu and select Preferences. The
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most common problem experienced when using this software is the unit scale mis-matched to the
manual scale on the hardware. Also, the software can sample ten points a second, a feature that
can crash older computers. It has been found that averaging the ten points per second yields an
accurate representation without risk of slowing or crashing computers.

76

2.2: LOW TEMPERATURE OXY-LIFETIME BINDING
Oxy-lifetime binding has been attempted using kinetic traces on the UV-VIS
spectrophotometer. The hypothesis tested was that with the temperature decreased sufficiently,
the lifetime of the sample could be recorded using the single second interval traces within the
Olis kinetic software. Below is the procedure utilized for this experiment.
First turn lamp on the spectrophotometer. It should warm up for at least thirty minutes to
allow for optimal repeatability. While waiting, acquire an ice bucket and fill with ice. Place
borate buffer and protein in the ice. Do not place heme or diacetyl-deuteroporphyrin IX
(DADPIX) in ice, as the dimethyl sulfoxide (DMSO) has a high freezing point and the mixture
will re-freeze. Next, acquire the low temperature sleeve and slide on top of peltier controlled
stage, aligning windows to allow light beam to pass through. Do not touch the windows, as they
are made of very sensitive optical glass from which oils are incredibly difficult to clean. On the
large chiller below the table, press the knob in once then rotate it to adjust the maintaining
temperature to -3˚C. Press the knob in once more to allow it to begin changing the setting. It is
prudent to add some antifreeze to the chiller, as most lab users only take the chillers to room
temperature. Next, adjust the peltier temperature control above the table to -15˚C in 2˚
increments. To turn on the peltier, press the run/stop button to have the red light flashing for the
unit to be on and begin changing temperatures. If the instrument signals “Low Flow”, then the
unit was unable to regulate the temperature at the rate desired. In that case, turn it off and then on
again and slowly work down to -15˚C. It will help if the chiller below the table is well below
room temperature.
Prepare a blank sample to minimize background signals from the UV-VIS
spectrophotometer. Acquire a 3 mL cuvette, fill with chilled borate buffer, and place in UV-VIS
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spectrophotometer. This step assumes there are two identical cuvettes and thirty minutes have
not elapsed since preparation of the samples. If there is only one 3 mL cuvette, it will be
necessary to run the blank, clean it, and prepare the sample as described in the next step.
To prepare sample, first acquire a 3 mL cuvette, then fill with 0.9 mL 100% ethylene
glycol and 2.1 mL complex. Add a very small clean stir bar that is usually kept by the sink. ,
Avoiding the creation of bubbles, gently flip upside-down and right side up until thoroughly
mixed. Try to minimize fingerprints while still holding the cuvette securely, as fingerprints need
to be removed with Kimwipes. Ensure the cap of the cuvette is the type that has puncture-able
rubber in the center. Place the sample in the sample holder on the stage. The low temperature
peltier controller above the table has a stir bar controller which should be set to the maximum of
10 in order to facilitate maximal stirring, but it will not be sufficient due to the size of the stir bar
and the viscosity of the solution.
As the temperature of the sample is lowered, condensation will form around it, making
the UV-VIS readings inaccurate. To deter this reaction, dry air is blown around the sample
chamber. To do this, remove the tube from the air connection at the wall and gently turn on the
air. When it is just barely flowing, reconnect the tube. The pressure coming out is enough to
blow the connections, so pay careful attention to the glass fittings that are rubber banded together
by the nitrogen train. If the Dri-Rite is pink instead of blue, it will need to be replaced with fresh
that will absorb any liquid in the air.
Next, turn on the nitrogen gas train. Begin by opening a valve after the gas train to
prevent excess pressure from building up within the glass bubblers. Next, open the valves at the
nitrogen tank; ensure the pressure is below the rating of the glass bubblers. The end of the train
should be in de-ionized water and should begin to bubble, indicating the gas is flowing. Pour 4
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ml buffer into a falcon tube and degas it by inserting a clean bubbling needle into the buffer. This
needs to be kept cold. The buffer can be prepared ahead of time for Sodium Dithionite. This
must be degassed for at least fifteen minutes.
Once the system has reached -15˚C, blank the system using the prepared blank and the
stir bar spinning. This will eliminate small noises it may cause later in the sample. Next, insert
the sample with the stir bar into the cold stage and let it reach -15˚C. While it is reaching
temperature, degas it by running the primary nitrogen line in to it and a secondary line out of it
and into the buffer. Since the sample has protein in it, do not allow the nitrogen to bubble the
sample; instead, have it flow on top of the sample. Once the nitrogen has flowed over the sample,
at least fifteen minutes, take a spectrum of the sample, which is the oxidized spectrum.
Once the sample is reduced, oxygenated buffer will be added to the sample to determine
binding. To create the oxygenated buffer, a serum bottle of buffer will be needed. Bubble oxygen
directly into the buffer for at least ten minutes to ensure complete oxygenation. When the
oxygenated buffer is added, it will be need to be done immediately after removing the oxygen
bubbler, as the serum septum does slowly leak. Additionally, the buffer will need to be
transferred with a 10 or 25 mL gastight syringe. Again, this is done after reducing the sample,
but since the preparation takes more than ten minutes, it is prepared before reducing the sample.
To reduce the sample, remove the Sodium Dithionite from the decanting jar and promptly
seal the jar by sliding it shut. Taking a clean micro-spatula, scoop a tip-full into the cold,
degassed buffer and seal it. Shake the falcon tube to ensure all the powder has been dissolved.
Using a 10 or 25 uL gastight syringe, add 1 uL of the sodium dithionite buffer at a time to
the sample. Because the sample is currently at -15˚C, the best method of adding the buffer is to
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drip the drop above the sample and then lower the needle into the liquid. The liquid will freeze in
the needle otherwise.
To ensure the sodium dithionite is homogeneously mixed within the sample, remove the
cuvette and gently flip it upside down and right side up and return it back to the holder. Do this
after firmly cleaning the path lengths with a Kimwipe, as condensation will form when removing
it from the dry, cold environment.
Take a spectrum of the sample on the UV-VIS spectrophotometer to determine if the
sample is reduced. A reduced spectrum will have a characteristic shift of the soret peak with the
formation of smaller Q bands as seen in Figure 34. Continue to add additions of sodium dithionite
until the spectrum shift appears to be complete. The amount of sodium dithionite buffer will vary
with each preparation, as it is dependent upon the degassing and the amount of solid added to the
volume of buffer. In Figure 34, the sample needed 10 uL in order to be completely reduced. The
spectrum is displayed only from 350 to 750 nm, as sodium dithionite has a large peak in the 300340 nm range.
Once reduced, change the set up of the spectrophotometer to take kinetic runs. Select
“Repeated Scans,” then “Repeated scans as a function of: “Time.” Change the top number to 40
and the bottom to 120. These settings will take a scan every three seconds for two minutes.
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FIGURE 34: REDUCTION OF HFHF
Approximately 60 uM HFHF protein with diacetyldueteroporphyrin (DADPIX) is reduced with
sodium dithionite. Indications of reduction can be seen in the shift of the soret peak from 424 to
448 nm and the growing in of the Q bands at 550 and 590 nm.
Now that the sample is reduced, oxygen will be bubbled through the sample. Retrieve the
septum with oxygenated buffer and 10 mL syringe. Fill the syringe with oxygen gas. A very long
needle is essential because it needs to reach the bottom of the cuvette.
Insert the 10 mL needle to the bottom of the cuvette, insert an outlet needle, trying to keep
a finger over the outlet to prevent oxygen leaking in, and select start on the kinetic trace. Quickly
bubble 5 mL of the oxygen gas through the sample while avoiding bubbling solution out the top
outlet needle. It is possible to slightly peak in by taking off the insulator’s cap, not the cuvette’s
cap, as removing the cuvette cap will oxidize the sample and require restarting the process.
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Ideal data will have clear oxidized and reduced peaks with an additional steady peak that
the complex appears to stay in for an extended period of time, indicative of third state, wherein
which the reduced iron formation binds with oxygen.
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FIGURE 35: OXY-LIFETIME
FHFH protein with a concentration of 63 uM with diacetyl-dueteroporphyrin (DADPIX).The
anerobic sample was held at -15˚C, reduced with sodium dithionite and 5 mL of oxygen gas was
bubbled through, Spectra were collected every 12 seconds for nine minutes. This data is
inconclusive regarding an oxy-ferrous binding state.
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APPENDIX 3: LAB PROTOCOLS

3.1 ANTIBIOTIC STOCK SOLUTIONS

3.1.1: CARBENICILLIN STOCK SOLUTION (50 MG/ML)
Dissolve 2 g in 40 ml de-ionized water. Sterile filter the solution and aliquot 1 ml into
green 1.5 ml eppendorf tubes. Store in -20˚C.

3.1.2: CHLORAMPHENICOL STOCK SOLUTION (35 MG/ML)
Dissolve 1.4 g in 40 ml 100% ethanol. Sterile filter the solution and aliquot 1 ml into red
1.5 ml eppendorf tubes. Store in -20˚C.

3.1.3: AMPICILLIN STOCK SOLUTION (100MG/ML)
Dissolve 4 g in 40 mL de-ionized water. Sterile filter the solution and aliquot 1 ml into
green 1.5 ml eppendorf tubes. Store in -20˚C.

3.1.4: KANAMYCIN STOCK SOLUTION (50MG/ML)
Dissolve 2 g in 40 ml De-ionized water. Sterile filter the solution and aliquot 1 ml into
blue 1.5 ml eppendorf tubes. Store in -20˚C.
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3.2 PROTEIN/SDS-PAGE GELS

3.2.1: PROTEIN GEL STAIN:600 ML
Combine 1.2 g coomassie blue, 300 mL methanol, 60 mL acetic acid, and 240 ml deionized water. This can be reused for three to six months.

3.2.2: PROTEIN DE-STAIN: 1 L
Combine 400 ml methanol, 100 ml acetic acid and 500 ml de-ionized water.

3.2.3: BLUE SILVER FIXING SOLUTION
Solution can be made at any volume using the following ratios: 60% water, 30%
methanol and 10% acetic acid.

3.2.4: BLUE SILVER STAIN
Start with 100 ml de-ionized water. Add 100 ml phosphoric acid and mix. Add 100 g
ammonium sulfate, mix until dissolved. Add 1.2 g coomassie R250 mix until mainly in solution.
Bring the volume up to 800 ml with de-ionized water and mix. Add 200 ml methanol.
This should be stored in a dark bottle. To stain, soak the gel in fixing solution for 1 hour,
then soak in the stain solution for at least 2 hours and destain using water. This is more sensitive
than the regular coomassie method.
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3.2.5: MES/SDS RUNNING BUFFER (20X) (1 LITER)
Mix together 195.2 g of MES (1 M), 121.2 g TRIS Base (1 M), 20 g SDS (69.3 mM) and
6g of EDTA (20.5 mM). Bring the final volume up to 1 liter with de-ionized water. This will
take time to dissolve; heating the water will decrease wait time.

3.2.6: LOADING BUFFER (TO MAKE A 4X STOCK)
In order to make a 4 x concentrated stock, combine 62.5 mM Tris-HCl; pH 6.8 (2.5 mL 1
M Tris-HCl; pH 6.8), 2% SDS (0.8 g SDS, sodium lauryl sulfate), 10% Glycerol (4.0 mL 10%
Glycerol), and 0.02 % Bromophenol Blue, 8.0 mg. Add de-ionized water to bring volume to 8
mL. Aliquot 800 uL into 1.5 mL epis and freeze. Add 200 uL bME (beta mercaptoethanol) before
use.
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3.3GROWTH MEDIA

3.3.1: LB (LURIA-BERTANI) SOLUTION
Combine the following into 500 mL de-ionized water: 10 grams bactotyptone or bacto
peptone, 5 grams of yeast extract, and 10 grams of NaCl. Adjust to 7.5 pH with NaOH. Adjust
final volume to 1 L with de-ionized water. Pour out in 100 ml flasks and autoclave.

3.3.2: LB(LURIA-BERTANI) AGAR (FOR PLATES)
Make 500 mL in 1 L flask. Add 5 g bactotryptone, 2.5 g yeast extract, 5 g NaCl and 7.5 g
Bacto Agar (this is just agar). Adjust to pH 7.5 with NaOH. Autoclave the solution with a stirring
bar inside the container. Two stacks of plates will be created with 500 mL volume.
Once out of autoclave, slowly cool to baby-bottle warmth, stirring to prevent
solidification so it does not hurt to touch. Only once to baby-bottle warmth is it time to add
antibiotics if making antibiotic plates. Pour solution to form a half-moon in the plate, then rotate
plate to cover full surface.

3.3.3: 40% GLUCOSE
Slowly add 400 g of glucose or sucrose to 600 ml of de-ionized water while stirring until
dissolved. Add de-ionized water to make a final volume of 1 L. Autoclave the solution.

3.3.4: TPP SOLUTION (PER LITER)
Add 20.0 g bactotryptone, 15.0 g yeast extract, 8.0 g NaCl, 4.0 g Na2HPO4, and 2.0 g
KH2PO4. Adjust to pH 7.5 with NaOH. Autoclave the solution. After autoclaving, (for growth)
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Add 1% glucose (25ml 40% sterile stock solution) and whatever antibiotic you are selecting
against.

3.3.5: M9 OR MINIMAL MEDIA(PER LITER)
Add 12.0 g disodium phosphate Na2HPO4, 6.0 g monopotassium phosphate KH2PO4, 0.5
g NaCl, and 1.0 g 15N NH4Cl use heavy isotope for NMR samples. Adjust pH to 7.4 and
autoclave. Wait until the solution approaches room temperature or just before use and add sterile
solutions of: (per liter) 25 mL 40% glucose, 2 mL trace metal solution (500X) and 1 mL vitamin
solution (1000X).

3.3.6: METAL STOCK SOLUTION (100 ML)
Combine the following:
8 ml concentrated HCl
5 g FeCl2·4H2O
184 mg CaCl2·2H2O
64 mg H3BO3
40 mg MnCl2·4H2O
18 mg CoCl2·6H2O
4 mg CuCl2·2H2O
340 mg ZnCl2
605 mg Na2MoO4·2H2O
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Bring to a volume of 100 ml with de-ionized water. Initially, the solution will be green
and will need to be stirred for several hours before everything dissolves. Store the metal stock
solution at room temperature.
*The metal salt is not as important as the metal itself. If no iron chloride is available, use
iron sulfate, for one example.

3.3.7: VITAMIN SOLUTION (1000X) (1L)
Combine the following:
1.1 mg biotin
1.1 mg folic acid
110 mg PABA para-aminobenzoic acid
110 mg riboflavin
220 mg pantothenic acid
220 mg pyridoxine HCl
220 mg thiamine HCl
220 mg niacinamide
Add 500 mL de-ionized water and 500 mL high-purity ethanol and filter to sterilize.

3.3.8: TRACE METAL SOLUTION 500X (500 ML)
Add 10 ml Metal Stock Solution (above) to 26.8 g MgCl2·6H2O then add de-ionized
water to 500 ml. Filter the solution to sterilize and store at room temperature.
Note that the Metal Stock Solution is used only to prepare the "O" solution and is not
added to the minimal media.
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Expect yield to drop about 50% for the same expression systems in LB or TPP. Also,
doubling times increase to 40-50 minutes.

3.3.9: TPP MEDIA GROWING INSTRUCTIONS
From fresh plate, pick one colony and grow in 5 mL LB and appropriate antibiotic for at
least six hours at 37ºC. It is recommended to do this process during the day. Add the 5 mL to 100
mL LB and grow overnight with antibiotic. Next, add 50 mL from the 100 mL LB to 1 L TPP in 6
L Erlenmeyer flask that has the antibiotic that is being selecting against and glucose (25 mL of
40% glucose, equivalent to 1% w/v). Add 1% metal stock and vitamin stock. Allow E.coli to
grow until OD600 is approximately 1 but not higher. The waste is bio-hazardous, so add bleach
to liquid to neutralize. Sterile pipettes such as 10 mL and 25 mL are not bio-hazardous unless they
came in contact with E.coli. Induce the 1 L of growth to produce protein with 200 mg of IPTG
(0.5 mM). Induce for 3-6 hours, depending on protein. Spin down at 10,000 rpm for ten minutes
in Sorvall SLA-3000 and collect bacterial pellets. To optimize expression of new protein, collect
1 mL samples every hour and run all samples on a SDS-PAGE to compare expression levels.
Freeze each sample to prevent growth while waiting to collect subsequent samples. For proteins
that are difficult to express, try expression at lower temperatures such as 30/25°C. It is likely to
need to induce for 4-5 hours at lower temperatures,.
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3.3.10: MINIMAL MEDIA GROWING INSTRUCTIONS:
Preheat the 100 mL and 1 L M9 media for minimal lag/delay. Add the glucose, divalent
metals, and antibiotics to minimal media as close as possible to use.
With the appropriate antibiotic, grow 5 mL LB cultures of bacterial strain at 37ºC until
cloudy, at least 6 hours, during the day. Use sterile technique and transfer 2 mL of the 5 mL to
100 mL of minimal media. Add antibiotic and grow overnight. Using sterile technique, transfer
50 mL of the 100 mL growth to 1 L M9, add glucose, antibiotic, metals, vitamins (25 mL of 40%
glucose equivalent to 1% w/v). The final volumes of metal stock and vitamin stock should be
1%. If using C13 glucose, add 2.0 g C13 glucose.
Grow to OD600 greater than 0.6 and less than 1. This will take longer than TPP;
approximately twice as long. Induce for an additional two hours, six to eight hours total. Again,
10 mL and 25 mL sterile pipettes are not bio-hazardous unless they came in contact with E.coli.
Liquid waste is bio-hazardous, so add bleach to neutralize.
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3.4: FRENCH PRESS INSTRUCTIONS

3.4.1: DNASEI (2 MG/ML)(200X)
Place 20 mg DNase I in 10 mL 20% glycerol and 75 mM NaCl. Aliquot the solution into
1 mL eppindorfs and freeze it at -20°C. To digest DNA during bacterial lysis, add to pellet for a
final concentration of 10 µg/mL in lysis or wash buffer, including 5 mM MgCl2.
3.4.2: NATIVE LYSIS BUFFER 10X (PER LITER) FROM QIAGEN
Combine 500 mM NaH2PO4, 69.0 g NaH2PO4·H2O (MW 137.99) and 3 M NaCl 175.4 g
NaCl (MW 58.44) and Add 0.02 g Azide NaN3 to 1 L of de-ionized water. Adjust to pH 8.0 with
NaOH.
Wash buffer can be substituted for this buffer.

3.4.3: PELLET PREPARATION
Combine and resuspend the bacterial pellets in 20-30 mL of wash buffer. Add the DNase
stock solution to reach 1X concentration. Add minimal amount of Pefabloc-- roughly a
micospatula tip. Rotate in cold room for thirty minutes. This step ensures homogenous
suspension. While this is rotating, prepare the French Press.

3.4.4: PRESS PREPARATION AND USE
The French Press often causes splashes of liquid. It is therefore strongly recommended
that proper personal protective equipment is utilized, including lab coat, safety glasses, and
gloves.
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First, retrieve the French Press cell from cold room. Place the cell in the press from the
rear of the press. Secure the cell in place by tightening the finger screws on the top plate.
Remove the outlet valve and replace the 1/8th” nylon ball with a new one. To remove the ball
from the valve, it may be easiest to heat the end of a metal paperclip red hot then insert into the
nylon ball. Wait for the ball and clip to cool completely, then spin the clip left and right to loosen
the ball from the valve. Wash the French Press cell with 20 mL of ethyl alcohol, and two times
20 mL de-ionized water.
When using the cell, first ensure all valves are closed. Next, open the inlet valve on the
back of the cell. Pull the cell plunger up to draw in liquid. The plunger shaft has volume
measurements listed on one side that can be used as reference for amount of liquid pulled into
the cell. Once 20-30 mL of liquid has been pulled in, close the inlet valve. Turn the press on to
medium and allow it to compress the cell and bring the pressure over 1000 psi. For washing the
cell, the press can be left on medium. Open the outlet valve ¼ turn at a time until flow starts. The
valve can continue to be opened further as long as the pressure remains above 1000 psi. If any air
is in the cell or was pulled in with the liquid at the end of the press run, air will be expelled
quickly, often causing a splash of liquid.
Once the cell is clean, load 20-30 mL of bacterial pellet resuspension on the cell. Turn the
press to medium and allow pressure to stabilize. Then turn to it to high. Slowly open outlet valve
in small ¼ turns until flow starts. Using outlet valve, to control flow, do not allow pressure to
drop below 1000 psi. Press the total sample three times. Clean the cell by the reverse of the
starting procedure 2x 20 mL de-ionized water, 1x 20 mL ethanol. Wipe down all pieces with
ethanol. Store all cell pieces in the cold room.
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Take the pressed sample and spin down at 15,000 rpm in SA-600 rotor for thirty minutes.
Because of the very high speed of the rotor, it is very crucial to ensure samples are balanced. It is
recommended to use the digital scale to balance the samples. Upon completion of centrifugation,
separate the supernatant from the debris. Check to ensure there is no suspended material. If there
is, re-spin or filter using cheesecloth. Run the supernatant over prepared nickel column as soon
as possible. Save the precipitate to resuspend in wash buffer with 6 M urea to run SDS-PAGE
protein gel in order to ensure most of the protein is in the supernatant and less in the precipitate.

3.5: HIS TAGGED PROTEIN PURIFICATION

3.5.1: 5X WASH BUFFER(PER LITER)
Combine 250 mM NaH2PO4 34.50g, 1.5 M NaCl 87.66 g, 100 mM Imidazole 6.808 g,
and 0.1 g Sodium Azide. Adjust to pH 8.0 with NaOH. This is prepared in 6 L batches and stored
for future dilution.

3.5.2: 1X ELUTION BUFFER(PER LITER)
Combine 50 mM NaH2PO4 6.9 g, 300 mM NaCl 17.53 g, 250 mM Imidazole 17.00 g, and
0.02 g Sodium Azide. Adjust to pH 8.0 with NaOH. This is prepared in 6 L batches and stored
for future use.

3.5.3: 1X NI-NTA REGENERATION BUFFER (PER LITER)
Combine 6 M Guanidine Hydrochloride 573.18 g, 0.2 M Acetic Acid 11.4 mL. Adjust to
pH 7.4. The guanidine displaces a large volume of water. As a result, begin with 200 mL of hot
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de-ionized water and with high stirring, slowly add solids. Once everything has been added, fill
to 1 L with additional de-ionized water.

3.5.4: GRAVITY COLUMN CELL LYSIS SUPERNATANT PURIFICATION(NATIVE)
First, ensure the gravity column is clean and recharged, the frit is clean, and the nickel is
blue. If the column runs slowly, the frit is most likely clogged. Pull a vacuum to suck 0.1 M
NaOH up through the back of the frit, the outlet, and allow it to drain out. Repeat this process
multiple times until the liquid flows out very quickly. Then rinse with de-ionized water.
Equilibrate the column with 1x wash buffer by using at least 4 column volumes. Discard
the flow-through of the equilibration. Close the column. Load 10-20 mL of lysis supernatant on
column. It is recommended to split the total volume of the French Press in half to prevent
overloading the column. Stir to ensure maximal binding opportunities. Collect the flow-through
in labeled falcon tube. Store the sample on ice.
Close the column. Wash the column with four column volumes of 1x wash buffer. Stir
thoroughly. Collect expelled wash in labeled falcon tube. Store it on ice. Close column. Very
gently add half of a column volume of 1x elution buffer. Do not stir. Let the elution on the
column sit for at least five minutes. Collect ten fractions of 5 mL elution. You will need to add
Additional 1x elution buffer will have to be added after first half column volume travels through
the column. Label the fractions or rack. Store the fractions on ice or in the cold room.
Clean column with a quick regeneration protocol.
Run on an SDS-PAGE protein gel lysis debris (resuspended in wash buffer with 6-8 M
urea), lysis supernatant, flow-through, wash, elution fractions 1-10 on 4-12% SDS-PAGE gel.
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3.6: SDS-PAGE GEL PROCEDURE
Turn on hot block and allow it to reach 85C and fill wells with de-ionized water. This can
be done while collecting samples. Prepare gel samples. If the protein has not been cut, it will
likely need to be diluted. An example sample would be 5 uL dye, 5 uL de-ionized water, 5 uL
sample. Dye is typically left on the bench, but if none is available, it is stored in the -20˚C and
can be made following the procedure for preparing Loading Buffer.
Heat samples at 85°C for five minutes. If the sample turns yellow, it is slightly acidic, but
it will turn blue again when running on the gel. It should not be an issue. Centrifuge for 4-5 sec
to ensure sample is all at the bottom of the eppindorf tube.
Acquire SDS-PAGE gel from cold room; remove comb holder, and white tape. Insert into
gel box with labeling facing the outside. Ensure running buffer is cold and not above room
temperature. Add or replace running buffer with running buffer stored in cold room. Fill the
middle well to top; if buffer doesn't stay in center, ensure the white clamp is tight and the spacer
is in place.
Add 12 uL of samples to 14 wells and 8 uL of molecular weight marker to one well.
If running multiple gels, strategically placing weight marker at the end on one and middle on the
other will quickly differentiate gels.
Turn on the power supply and connect the lid; the voltage should be approximately 200
mV and the gel will run for approximately thirty minutes. You want to run the dye to the bottom
without having it run off. If it does run off, it is possible to determine if the gel will still show the
results of interest by comparing the location of the weight markers of interest with location on
the gel.
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Turn off the power; unclamp and remove the gel. Crack gel by using the pallet knife and
twisting at each corner. Remove the gel by using the pallet knife to pry one of the lower corners
away, and then push knife through slot.
Place the gel in a 1 L beaker and cover with stain. Cover the beaker with cling wrap.
Microwave the beaker for thirty seconds. Place it on agitator for ten minutes.
Pour the stain back into bottle. Rinse the gel with water and cover it with destain. Replace
the cling wrap. Microwave it for thirty seconds. Agitate for ten minutes.
Discard destain. Rinse the gel with water. Cover the gel with destain. Replace cling wrap.
Microwave it for thirty seconds. Agitate for ten minutes.
Discard destain. Rinse the gel with water. Cover with de-ionized water. Replace cling
wrap. Agitate for two hours. Results may be visible immediately.

3.7: DIALYSIS PROCEDURE
First prepare dialysis buffer. Select a stir bar, but do not use the largest bars as they are
more likely to remove dialysis clips or tear tubing. Wear gloves when handling tubing; water
contain 0.05% Azide, and gloves will also prevent enzymatic degrading of protein and tubing.
Remove dialysis tubing from the cold room; cut an acceptable length (9.3mL/cm for larger
tubing). Remember to allow space for air, water expansion, and four clips. Ensure there is liquid
in dialysis storage bag. Seal it and return it to the cold room.
Rinse the outside of the cut dialysis tubing. Clamp fingers over one end and fill with deionized water to ensure there are no leaks and release fingers, letting water rinse the inside.
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Clamp one end with two clamps. White and pink clamps are for labeling only, not for
holding the tubing shut. Alternate the direction of the clamps to maximize likelihood that one
clamp will not fall off.
Using a small funnel, fill the dialysis tubing. Work over a Pyrex dish to catch liquid if the
tubing slips or overflows. Clamp the top of the tube, allowing air inside the tube to help with
buoyancy.
Place the tube in the prepared dialysis buffer. Ensure the buffer is labeled and covered to
prevent debris for entering. Place on stirrer in cold room for at least six hours. Protein will
degrade if left for long periods, so do not dialyze over a weekend.

3.8: CUT PPROTEIN MINI-BIO-RAD PURIFICATION
Ensure the column is clean without air on the column or lines and the nickel is blue. If
there is air on the column, remove from the mini-bio-rad and place the inlet and outlet lines in
de-ionized water. Seal the bottom of the column using a black fitting. Unscrew the top of the
column, which is the end with the plunger. The cap is double-threaded; the lower half screws
clockwise onto the threads of the glass column whereas the top threads are counter-clockwise in
order to push the plunger down and compress the column. Pull the unscrewed plunger assembly
off the glass walls of the column. Be very careful to pull straight up, as applying even very little
force to the sides of the glass threads will cause them to break.
Once the nickel column is accessible, add degassed de-ionized water and stir to remove
air within the resin. Gently fill the column completely to the top with degassed de-ionized water.
Let the column sit carefully until the nickel has settled to the bottom. The glass has no grooves to
help hold it with clamps, so be very careful if clamping it to hold it in place.
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When the nickel is settled at the bottom, put on gloves and work over the sink. Take the
plunger and carefully align it so it is directly above the opening of the column. Apply pressure so
the plunger is inserted straight and does not apply force to the sides of the column. Liquid will
squirt out the top of the plunger assembly; as long as the frit on the top of the assembly is intact,
the liquid should only be de-ionized water and whatever buffer the nickel was previously in. Use
manual pressure to force the plunger down as far as possible without expelling all the liquid
above the nickel. If at any time air bubbles appear it is possible to try and press them out, but
often starting over will be necessary. For the last liquid above the nickel, use the plunger threads
and threads on the glass to force down the plunger the final amount without compressing the
nickel.
When the column is together and in the mini-bio-rad without air, equilibrate it with 1x
degassed wash buffer, using at least four column volumes. Turn on the lamp and ensure it is
zeroed in order to visualize absorbance. Discard the equilibration flow-through. Load cut protein
and collect output in a labeled falcon tube once absorbance begins to rise. Label the tube “low
concentration”.
Store on ice. This fraction contains a low concentration of protein that does not have a
His6 tag on it and therefore does not stick to the column. The remainder of the fraction should be
wash buffer.
Switch to a second labeled falcon tube when absorbance is above 0.1. Label the tube
“high concentration”. Store on ice. Continue collecting in high concentration tube as the
absorbance plateaus. If after the absorbance plateaus it begins to increase again, switch to a new
falcon tube; label “overloaded”. The high concentration fraction should contain high
concentration of protein that does not have a His6 tag on it and therefore does not stick to the
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column. The remainder of the fraction should be wash buffer. If an overloaded fraction is needed
and collected, this is indicative of running such a high volume of protein over the column that the
His6 tags and protein that still has His6 tags attached have run out of binding opportunities; thus
are visible in the absorption by the increase after the plateau. This sample is important to keep
separate from the high concentration sample as it will need to be rerun over the column to
separate the His6 tags and un-cut protein.
When approaching the end of the protein, ensure no air is pulled into pump. It is possible
to add a small amount of wash to ensure all protein is put on column. Once all protein is on
column, wash with 1x degassed wash buffer. Continue collecting output in either the high
concentration falcon tube or overloaded falcon tube until absorbance is below 0.1.
Collect output below 0.1 in a low concentration falcon tube until the absorbance appears
to plateau. If the column was overloaded, ensure the low concentration is separated from the
initial low concentration, as the later fraction will also need to be rerun over the column.
Absorbance may not return to zero.
When the absorbance appears to have plateaued at a low value, load 1x degassed elution
buffer on the column. When the absorbance begins to spike, collect output in a falcon tube
labeled “fusion protein”. Once absorbance plateaus off near zero, run a quick column regen
protocol and discarding output.
Ensure lamb for absorbance is off.
Run an SDS-Page protein gel with the following fractions: lysis debris, lysis supernatant,
pre-cut, cut, low concentration, high concentration, overloaded, and fusion protein.
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3.9: BIO-RAD CELL LYSIS PURIFICATION
Switch valve to Purge (P) by clicking resize button to reveal valve control. Begin by
checking that the pumps are pumping normally by allowing both pumps to pump individually for
2-5 minutes while observing the pressure read out. If there are major fluctuations in pressure, do
not use; seek assistance. Make sure you have enough buffer volume to run the purification; more
than 500 mL each. All new buffers are to be vacuum-filtered to remove particulate and to de-gas.
De-gas each buffer for twenty minutes.
Switch valve to Load (L) by clicking resize button to reveal valve control. The nickel
column is equilibrated with two column volumes of 1X wash buffer. French pressed and spun
down supernatant is loaded onto nickel column using the auxiliary pump with a loading speed 11.5 mL/min. Turn on the quadtec detector from biorad manual screen.
Switch valve to Inject (I) by clicking resize button to reveal valve control. Using the
auxiliary pump, add 1X wash buffer to column until A280 absorbance drops to 2.5-2.0. Fill one
rack completely with tubes. If running overnight, add eleven to second rack. In the biorad
manual screen, click file open , select program Gradient.4, and select new run. Label and date
both fields. Click the green play symbol.
When collection is over, go to post run to print the read-out. Combine the tubes that are
under the peak. If multiple peaks or if it is the first time running a protein over the column, a gel
should be run to determine where the protein of interest came off.
Clean the pumps of buffer by purging the pumps with de-ionized water and shoot 5 mL
de-ionized water into wash ports on top of the pump heads.
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3.10: TEV CUTTING OF HIS TAGGED PROTEINS
Collect dialyzed protein in 250 mL screw top bottle. Save dialysis tubing for after cut.
Remove a 10 uL sample and set aside for a SDS-PAGE protein gel. Add 0.5 M DTT stock
solution to protein solution to make final DTT concentration of 1 mM. Add 2% V/V TEV
enzyme. Allow the TEV enzyme to cut at room temperature for a minimum of six hours with
nutation. Alternatively, the solution can cut overnight in the cold room with gentle stirring.
Run an SDS-Page gel comparing pre-cut sample set aside earlier and a sample that has
been cut. Put cut protein solution to dialysis tubing and dialyze into 4 L 1X wash buffer. This
will remove the excess DTT and save the nickel column from being reduced by DTT.

3.11: BIO-RAD CUT PROTEIN COLLECTION
Follow starting procedure for cell lysis purification in BIO-RAD purification. Once the
pumps have been primed and verified to be functioning properly and the column has been
equilibrated, select program cut protein collection.1. Label and date both fields. Click start
button. The program will run wash buffer for ten minutes. Get sample ready by collecting it into
50 mL tube(s) or 250 mL flask. Using auxiliary pump, run cut protein over column no faster than
1.5 mL/min. If more than eighty minutes is needed, pause the program while continuing to pump
sample onto the column with auxiliary pump. Watch the A280 read-out and collect into protein
fraction as it comes off.
Run wash buffer through column. Clean column by rinsing with elution buffer then
washing with wash buffer. Turn off quadtec detector. Clean pumps of buffer by purging the
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pumps with de-ionized water and shoot 5 mL de-ionized water into wash ports on top of the
pump heads.

3.11.1: GENERAL PROCEDURE FOR USING BIO-RAD DUAL FLOW FPLC
Make sure that you have the right buffers that have been vacuum-filtered to remove
particulates and to de-gas. Ensure that all fittings are finger tight. Check manufacturer’s
instructions for pressure and flow rate settings for the column being used. To change buffers,
pull 10 ml through the priming port with the 35 mL syringe to prime the pumps with the new
buffer. This is done by inserting the syringe, twisting the port open one turn, then pulling the
plunger to 10 mL; while still inserted, close the port to finger tight.

FIGURE 36: FRONT SCHEMATIC OF BIO-RAD

Using the manual screen, change valve to purge (P). Press the resize button to view the
valve controls and pump 1 mL/min pump A for about two minutes to check for stable pump
pressure. Repeat for pump B.
Set valve selector to Load (L) and turn on quad-tec detector. Make sure the column is
equilibrated properly-- usually 2-3 column volumes of buffer A. Set up rack of tubes and/or
separate collection container. Select program to be run-- Gradient.4: is for collection of his
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tagged protein, TEV Purification 1: for Harvesting TEV enzyme, Cut Protein Collection.1: for
collecting cut protein.
Name the run with the sample type and date in both fields. In the notes, enter the name of
the sample and any other relevant information. This can be done after the run is started. Click the
green play button at the top right to start the program. The stop button will end the program early
and save the read-out. The pause button will stop the read-out and the pumps. The hold button
will keep the read-out going but keep the pumps at their position until it is pressed again. After
collection of sample, wash the column with correct buffer. Set valve to purge and connect pumps
A and B to degassed de-ionized water bottle. Prime the pumps with water. Run 50/50 pumps A
and B for ten minutes. Use the syringe to run 5mL of degassed de-ionized water into pump head
to wash out ports. If the last two steps are not done, it will lead to salt build-up on the pump
heads and non-functioning of this equipment.

FIGURE 37: CLOSE UP SCHEMATIC OF BIO-RAD SAMPLER
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3.12: RECHARGING A NICKEL COLUMN
The Quigen handbook claims each column can complete five runs before needing
recharging. From experience, the columns can actually do more. When resin changes from light
blue to brownish grey, then it is time to recharge the nickel.

3.12.1: QUICK CHARGE
A quick charge begins by running two column volumes of de-ionized water through the
column. Next, two column volumes of 100 mM NiSO4 are run through the column. The nickel
sulfate is washed off with two column volumes of de-ionized water. Next, two column volumes
of regeneration buffer are run through the column. Finally, two column volumes of wash buffer
are run through the column to prepare it for use.

3.12.2: FULL CHARGE PROTOCOL
A full charge begins with thoroughly washing the column, using five column volumes of
de-ionized water. Next, three column volumes of 2% SDS are run through the column; then one
column volume of 25% ethanol, one column volume of 50% ethanol, one column volume of
75% ethanol, one column volume of 100% ethanol and one column volume of de-ionized water.
Next, five column volumes of 100 mM ETDA pH 8.0 are run over the column. Then, two
column volumes of 100 mM NiSO4 and two column volumes of de-ionized water are run
through the column. Finally, the column is equilibrated with two column volumes of wash
buffer.

3.12.3: NATIVE LYSIS BUFFER (PER LITER)
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Combine 50 mM NaH2PO4, 6.9g, 300 mM NaCl, 17.54 g and 10 mM imidazole, 0.68g.
Fill to 1 L with de-ionized water. Adjust to pH 8.0.

3.12.4: NATIVE BUFFER A (WASH) (10X PER LITER)
To make a 10x volume of buffer, combine 0.5M NaH2PO4, 69g, 3 M NaCl, 175.4g, and
200 mM Imidazole, 13.6g. Fill to 1 L with de-ionized water. Adjust to pH 8.0 with NaOH.

3.12.5: NATIVE BUFFER B (ELUTION) (5X PER LITER)
To make a 5x volume of buffer, combine 0.25 M NaH2PO4, 34.5g, 1.5 M NaCl, 87.7g,
and 1.25 M Imidazole, 85.0 g. Fill to 1 L with de-ionized water. Adjust to pH 8.0 with NaOH.

105

3.13: DNA GELS
3.13.1: 50X TAE BUFFER (TRIS-ACETATE-EDTA)
Combine 242 g Tris base (2 M), 57.1 ml acetic acid and 100 ml 0.5 M EDTA. Adjust to
pH 8.5. Adjust final volume to 1 Liter with de-ionized water.

3.13.2: AGAROSE GELS
Pour 550 ml 1x TAE buffer into 1 L beaker. Add 1.2% or 2% (W/V) of agrarose and
swirl. Microwave for two-minute intervals until all agarose is dissolved. Wear protective gloves.
Seal the gel box with tape and insert combs. Add 200 uL Ethidium Bromide. Be sure to wear
nitrile gloves, as this is bio-hazardous. Pour into gel box; check that all combs are properly
placed.

3.13.3: 10X DNA LOADING BUFFER
Combine 50% glycerol and 50% 10X TAE buffer, then add enough bromophenol blue
and xylene cyanol to make it stain dark blue. Any solids that came in contact with DNA gels are
bio-hazardous and must be properly disposed in the bio-hazardous waste containers.

3.14: BUFFERS
3.14.1: BORATE BUFFER: 4X(PER LITER)
Add 0.5 M KOH. Add this base first or the boric acid will not dissolve. Then add 1.0 M
Boric Acid and 0.4 M KCl. Adjust to pH 9.0.
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3.14.2: TEV WORKING BUFFER 20X (PER LITER)
Combine 1 M Tris-HCl, 121.1 g, and 10 mM EDTA, 3.72 g. Adjust to final volume to 1
L. Adjust to pH 8.0.
To use, dilute to 1x and add 0.5M DTT to make the final concentration 1 mM DTT.

3.14.3: LYOPHILIZATION BUFFER
Combine 20 mM Ammonium Bicarbonate and 2 mM glucose or sucrose. Adjust pH to
7.5.
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3.15: TEV PROTOCOL
The foundation for this protocol can be found in BioTechniques, volume 30, page 544.

3.15.1: RESUSPENSION BUFFER1:10X (PER LITER)
Prepare 0.5 M Tris-Cl, 60.55 g, and 3 M NaCl, 175.4 g to a volume of 1 L with de-ionized
water. Adjust to pH 8.0 with HCl.

3.15.2: RESUSPENSION BUFFER2: (INCLUSION BODY RESUSPENSION)PER LITER
Combine 6 M guanidine-HCl, 573 g, 100 mM NaH2PO4, 13.80 g, and 10 mM Tris-Cl,
1.211 g. Adjust to final volume of 1 L. Adjust to pH 8.0 with NaOH.

The following three have the same ingredients at the same concentrations. Make 1 L of
EQ buffer, do not pH it, and then pH 0.5 L to 8.0 for the EQ buffer, 0.25 L to 6.3 for wash
buffer, and 0.25 L to 4.5 for the Elution Buffer.

3.15.3: EQUILIBRATION BUFFER(EQ BUFFER)PER LITER
Combine 6 M urea, 363.6 g, 100 mM NaH2PO4, 13.80 g, and 10 mM Tris-Cl, 1.211 g.
As per the note above, separate 0.5 L and adjust to pH 8.0 with NaOH.

3.15.4: WASH BUFFER(PER LITER)
Combine 6 M urea, 363.6 g, 100 mM NaH2PO4, 13.80 g, and 10 mM Tris-Cl, 1.211 g.
As per the note above, using 0.25 L separate from 1 L made of EQ buffer, adjust to pH
6.3 with NaOH.
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3.15.5: ELUTION BUFFER(PER LITER)
Combine 6 M urea, 363.6 g, 100 mM NaH2PO4, 13.80 g, and 10 mM Tris-Cl, 1.211 g.
As per the note above, using 0.25 L separated from 1 L made from EQ buffer, adjust to
pH 4.5 with NaOH.

3.15.6: STORAGE BUFFER: MAKE 2 L, 1 L WILL BE GLYCEROL (PER LITER)
The amounts given here are per liter; to make this buffer, you will need to make 2 L, so
double the amount added. In 200 mL of de-ionized water, combine 0.1 M Tris-HCl, 12.11 g, 0.5
M NaCl, 29.22 g, and 0.5 mM EDTA, 0.1861 g. Many of these stocks are in solution form at
higher concentrations and can be added as a liquid to eliminate time waiting for solids to
dissolve. Once the solution is uniform, add 1 L of glycerol. Fill remainder to 2 L with de-ionized
water .Adjust to pH 8.5.
Place the buffer in the cold room, stirring and covered. Just before adding TEV, add 5
mM DTT in solid form. This will not dissolve immediately, but with stirring, it will not impede
function.

3.15.7: STEPS FOR TEV PRODUCTION
TEV is a natural protein and a protease that self-cleaves, so care must be taken to keep all
protein solutions cold at all times. All solutions, including the final dialysis buffer, should be at
4˚C before use and the enzyme should always be on ice if out of the freezer.

Grow E.coli with TEV genes included in 5 mL of LB with 5 uL of ampicillin for at least
six hours during the day. Use sterile technique to transfer the 5 mL into a 100 mL LB overnight
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growth with 100 uL ampicillin. Transfer 100 mL into a 2 L TPP with 2 mL ampicillin, and
glucose and metals and vitamins, at concentrations consistent with standard TPP growths.
E.coli is expressed until OD600 is approximately 1.0. Then induce with 400 uM
IPTG,0.1905 g for 2 L. Let the E.-coli induce for four to five hours. Centrifuge at 10,000 rpm for
ten minutes.
Resuspend the pellets in 25mL of 1x Resuspension Buffer 1 per liter of culture.
Production can be stopped at this point by flash freezing in liquid nitrogen and storing at -80°C.
Thaw frozen pellets in cool water and add 500 ug/mL lysozyme, 200 ug/mL DNase1, 50
ug/mL pefabloc, 20 mM MgSO4, and 2 mM CaCl. Stock solutions of MgSO4 and CaCl can be
found on the molecular biology bench. The solids generally are not measured out but rather a
micro-spatula tip of lysozyme, DNase, and pefabloc are directly added because of their high
activity.
Incubate the pellets for thirty minutes with agitation at 4°C. Lyse the cells by three freeze
thaw cycles. Freeze the solutions in liquid nitrogen until solid, then place the frozen samples in a
cool water bath to thaw them. This process is repeated three times.
Add triton X-100 to 1% and vortex for one minute. If this step is skipped or forgotten,
TEV purification will also purify a secondary protein that will give the TEV a color. The
efficacy of this combination is unsure and will make using the resulting TEV require further
purification in order to separate the secondary protein.
Centrifuge the vortexed solution at 10000xg for twenty minutes. Separate the pellets and
supernatant. If it is late in the day, this is the place to stop before finishing purification. Pellets
can be stored at -80°C. Store the supernatant also, as it will be run on a gel to ensure the protein
was in the pellet.
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Using Resuspension Buffer2, incubate pellets at 65° until fully dissolved. Fill each
centrifuge tube to the maximum allowable. Centrifuge for twenty minutes at 15000xg. While the
pellets are incubating, dissolving, and centrifuging, prepare the gravity column and buffers
needed. TEV buffers must be prepared fresh, as urea loses functionality over time. Equilibrate
column by running at least five column volumes of EQ buffer through the column.
Load supernatant onto equilibrated column. Collect the flow-through in a labeled falcon
tube. Wash the column with four column volumes EQ buffer. Collect the liquid exiting the
column in a falcon tube labeled “EQ buffer”. Wash the column with three column volumes TEV
wash buffer. Collect the liquid in a falcon tube labeled “wash buffer”. Close the column; put 0.5
column volumes on the column and wait five minutes.
Collect the elution in fractions, loading four additional column volumes on the column. If
running the Dual Flow Bio-Rad the procedure is named TEV purification.
Make storage buffer and put in cold room so that it is cold when it is needed. Do not add
DTT until just before use.
Run a SDS-PAGE protein gel on lysis supernatant, resuspended pellet, flow-through, EQ
wash, TEV wash, and fractions. Pool fractions containing TEV and adjust pH to 8.5 with NaOH.
Dialyze into storage buffer for four to eight hours. Precipitate is pelleted by centrifugation at
15000Xg and stored at -80˚C. Aliquot into 1 mL fractions and snap freeze with liquid nitrogen.
Precipitated final pellet is re-dissolved in EQ buffer and dialyzed into fresh storage buffer.
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3.16: COMPETENT E.COLI BY RBCL METHOD
Care should be taken to ensure that competent cells do not become contaminated. For this
reason, all items used in this protocol should be sterile, and hands and work surfaces should be
sprayed with ethanol. Solutions 1 and 2 should be filter-sterilized and kept at 4˚C.
Inoculate a 3 ml overnight culture with DH5a or E.-coli strain of choice. Add 1-5 ml of
this culture to 500ml of pre-warmed LB with 2.5 ml 1 M Mg++. Grow until OD600 reaches 0.5.
Chill the bacteria in ice water for fifteen minutes. Spin the growth at 3000 rpm for five minutes
at 4oC. Resuspend by mild vortex in 30-50 ml buffer I per 500 ml culture. Spin again at 3000
rpm for five minutes at 4oC. Resuspend in10 ml buffer II per 500 ml culture. Aliquot cells into
microfuge tubes, either 100 uL or 200 uL aliquots.
Freeze in a dry ice ethanol bath and store at –80oC. Competent cells should be tested
before use to check if they are competent or for any contamination.

3.17: TRANSFORMATION
3.17.1: TBUFFER I
To make 1 L of Buffer I combine 12 g of RbCl, 9.9 g of MnCl.4H2O, 30 mL of 1 M
potassium acetate, 1.5 g of CaCl.2H2O and 150 g of glycerol.
To make 100 mL of Buffer I combine 1.2 g of RbCl, .99 g of MnCl.4H2O, 3 mL of 1 M
potassium acetate, 0.15 g of CaCl.2H2O and 15 g of glycerol.
3.17.2: TBUFFER II
To make 1 L of Buffer II combine 20 mL of 1 M MOPS, pH 6.8, 1.2 g RbCl, 11g
CaCl2.2H2O, and 150 g of glycerol.
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To make 100 mL of Buffer II combine 2 mL of 1 M MOPS, pH 6.8, 0.12 g RbCl, 1.1g
CaCl2.2H2O, and 15 g of glycerol.
3.17.3: PROCEDURE
Thaw competent cells on ice; add 2 uL of DNA to 50 uL competent cells and incubate for
thirty minute on ice. Incubate for two minutes at 42oC. Incubate for five minutes on ice. Add 1ml
LB without antibiotics. Incubate in shaker for thirty minutes at 37oC. Spread 100 ul if doing
regular transformation or all if doing ligation transformation, on a plate with appropriate
antibiotic selection. Incubate overnight at 37oC.
This process needs to have controls run simultaneously to ensure that the transformation
works. A competent cell aliquot without DNA added should proceed through all the steps in
parallel with the competent cell that receives the DNA. When plating the cells, in addition to
each antibiotic plate, an LB plate without antibiotics should also be prepared. Thus, for one DNA
sequence going into one E.-coli strain, there should be two Eppendorfs of competent cells and
four LB plates, two with antibiotic and two without.

3.18: PYRIDINE HEMOCHROME ASSAY
Note that anything with pyridine is bio-hazardous, and needs to be properly disposed and
not put down the sink.
The purpose of this assay is to determine the concentration of heme in heme/DMSO
solution.

3.18.1: SOLUTION A
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Prepare 20 mM NaOH, 20% Pyridine in de-ionized water. There is a stock of this
solution.

3.18.2: SOLUTION B
Dilute 329 mg K3FeCN6 into 10 mL de-ionized water.
3.18.3: PROCEDURE
Dilute approximately 5 mg heme into 5 mL DMSO. Make sure to allow heme to reach
room temperature before opening it. Next, it is necessary to blank the UV-VIS
spectrophotometer. Using a disposable cuvette, add 958 uL of solution A and 2 uL of solution B
to cuvette. Mix solution through inversion. Collect reference along 0.4 cm path length. Next, the
oxidized absorbance must be collected. Add 40 uL of the heme solution to the cuvette. Mix
through inversion. Record the absorbance and 558 nm. If the absorbance is below 0.1, add a
known amount more of heme.
Next, the reduced absorbance must be collected. Cover the tip of a micro spatula with
sodium dithionite and add it to the cuvette. The sodium dithionite is kept in a desiccator and it is
important to close it right after removing the sodium dithionite. Mix through inversion; the
cuvette should turn red. Record the absorbance at 558 nm. The absorbance should be higher than
the oxidized value.
Repeat the blank, oxidized, and reduced absorbance measurements two more times after
emptying and washing the cuvette. Remember that the pyridine solution is bio-hazardous. Proper
personal protective equipment should be worn and the solution should be discarded in the biohazardous waste containers.
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Calculate the heme concentration using Beer’s Law, A = ∆𝛜∙L∙[c]. Recall the path length,
L is 0.4 cm. Absorbance A is the average of the difference of reduced absorbance less the
oxidized absorbance. The extinction coefficient, ∆𝛜 = 27.06cm-1mM-1. This will allow solving
for [c] for the heme concentration in mM.

3.19: MAKING GLYCEROL STOCKS
Using sterile technique, add 750 uL of sterile 80% glycerol stock to 2 mL glycerol stock
tube that has been labeled on the top and side. Add 750 uL of growth. Gently invert several times
to mix the glycerol and bacteria. Store in -80˚C.
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